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Abstract 
INVESTIGATION OF THE SHORT- AND LONG-TERM HEALTH OUTCOMES 
AMONG A NATIONAL COHORT OF VETERANS WITH AND WITHOUT 
CLOSTRIDIOIDES DIFFICILE INFECTION
Amina Rida Abdul Latif Zeidan, PhD
The University of Texas at Austin, 2021 
SUPERVISOR:  Kelly R. Reveles 
Clostridioides difficile infection (CDI) is an urgent public health problem in the 
United States (U.S.). C. difficile is now the most common organism implicated in 
healthcare-associated infections and the main source of antibiotic-associated diarrhea. 
Nearly half a million Americans suffer from and 29,000 die as a result of CDI annually. 
Importantly, CDI disproportionately affects the elderly population, with 70% of cases 
occurring in patients older than 65. CDI places a significant burden on patients in the 
short-term. While CDI commonly manifests as diarrhea, it can lead to more severe 
manifestations like megacolon, intestinal perforation, sepsis, or death. Importantly, CDI 
has been associated with impaired functional capacity in the short-term and poor overall 
quality of life, including physical, mental, and social functioning. CDI has also been 
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associated with prolonged gut microbiome dysbiosis. Dysbiosis has been previously 
associated with may aging- and frailty-associated conditions due to a strong biological 
link with the gut microbiome. Despite robust, short-term epidemiological studies, the 
long-term impact of CDI on healthy aging has not been investigated. To inform this 
knowledge gap, we addressed the hypothesis that CDI negatively affects long-term 
healthspan and lifespan. Our study aimed to define short- and long-term health outcomes 
of patients with and without CDI among a national cohort of veterans. This was a 
retrospective cohort study of adult patients presenting to any outpatient or inpatient 
Veterans Health Administration facility in the United States from October 1, 2002 to 
September 30, 2018. CDI patients were defined as those with an ICD-9-CM or ICD-10 
code for CDI plus a positive C. difficile stool test and active CDI therapy. A control 
group was created by identifying non-CDI patients and matching 2:1 based on 
inpatient/outpatient visit and fiscal year. The outcomes of this study included 1 month, 3 
month, 12 month, and 10-year aging-related conditions, frailty-associated conditions, and 
mortality. The association between CDI and these outcomes was assessed using a series 
of propensity score matched cohorts (1 CDI:1 control) and adjustment for covariates 
post-match using multivariable logistic regression. A total of 31,531 CDI cases and 
81,293 non-CDI matched controls were included for analysis. CDI was significantly 
associated with risk for mortality at 1 month (OR 3.75, 99% CI 3.23-4.34), 3 months (OR 
3.07, 99% CI 2.74-3.43), 12 months (OR 2.70, 99% CI 2.47-2.96), and 10 years (OR 
1.62, 99% CI 1.34-1.97). Though numerically higher among CDI patients, the risk for 
chronic aging-related conditions was not statistically significant at any follow-up period, 
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and there was no significant association between the number of CDI episodes and the 
development of aging related conditions. CDI patients had higher prevalence of any 
frailty-related condition at short-term follow-up periods and CDI was significantly 
associated with the development of frailty-associated conditions at 12 months (OR 1.27, 
99% CI 1.15-1.41). Finally, the number of CDI episodes was positively and significantly 
associated with VA frailty index at 12 months and 10 years (p<0.0001). In summary, CDI 
was associated with poor short- and long-term outcomes compared to a matched control 
group among a national cohort of veterans. This work is innovative because it utilizes 
robust data analytics on one of the world’s largest clinical cohorts of CDI patients. This 
research is expected to have a positive impact on human health by promoting appropriate 
CDI prevention and treatment. 
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Chapter 1:  An Introduction to Clostridioides difficile Infection 
PATHOGENESIS OF DISEASE 
Clostridioides difficile is a gram positive, spore-forming anaerobic bacterium 
commonly found in the environment. C. difficile spores are highly tolerant to extreme 
temperatures, many disinfectants and chemicals, and desiccation;1,2 therefore, spores have 
been previously reported in the community (e.g., post-treatment wastewater, treated 
compost, various soil sources),3-5 and in healthcare facilities (e.g., toilets, bathtubs, 
medical instruments, personnel hands). Due to this ubiquitous nature, there are several 
potential environmental exposure sites for C. difficile, including, but not limited to 
hospitals and long-term care facilities, which can contribute to both asymptomatic 
colonization of the host and potential symptomatic infection due to transmission via the 
fecal-oral route.  
The pathogenesis of CDI is strongly driven by a disruption in the healthy host gut 
microbiome. The human gut microbiome contains trillions of microbial cells that interact 
with the human host to prevent infection, limit accumulation of toxins, and modulate the 
immune response. Importantly, the microbiota are exclusively responsible for several 
metabolic functions, including metabolism of short chain fatty acids, organic acids and 
vitamins, and transformation of transforming bile salts, lipids, and amino acids.6 A loss of 
protective microbes, namely due to antibiotic exposure, results in a loss of C. difficile 
colonization resistance. Once colonization is established, C. difficile spores can germinate 
and produce new vegetative cells when the conditions become favorable. For example, 
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the primary bile acid taurocholate promotes germination7 while the secondary bile acid 
deoxycholate acts as a competitive inhibitor of taurocholate and suppressant of vegetative 
growth.8  
Vegetative growth of C. difficile results in production of toxins, including 
enterotoxin A and cytotoxin B. These toxins can cause disease in the host by disrupting 
signal transductions of the cytoskeleton and translocating toxin into the cytosol.9 The 
host’s immune response to cell uptake of these virulence factors involve increased 
inflammation, mucosal and fluid secretion, and damage to mucosal linings, which can 
result in diarrhea or more severe complications like sepsis/shock, acute renal failure, 
ileus, perforated intestine, or megacolon in humans.10 These responses result in 
symptomatic C. difficile infection (CDI), as described in Figure 1.1. It is important to 
note that toxin production is required for symptomatic infection in humans, and 
colonization alone does not qualify an individual as having clinical disease. Certain 








Figure 1.1. Microbiological pathogenesis of CDI. 
 
Importantly, CDI is a bacterial infection that is treated with antibiotics. CDI-
active antibiotics can continue to disrupt the host microbiome and prevent recovery; thus, 
C. difficile spores may persist and ultimately cause a subsequent recurrent infection (i.e., 
relapse) or patients may become colonized with a new strain (i.e., reinfection) due to 
limited colonization resistance. Approximately half of patients who recur within two 
months have relapse and the other half reinfection;11 however, relapse and reinfection are 
regarded as clinically indistinguishable and are referred to interchangeably in a clinical 
setting as “recurrence.”  
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DISEASE BURDEN AND COST 
In the U.S. alone, nearly half a million people suffer from and 29,000 people die 
as a result of CDI annually,4 resulting in approximately $4.8 billion in healthcare costs 
each year.5 CDI disproportionately affects older adults, with approximately 70% of cases 
occurring in patients older than 65 years.6 Our recent study found that CDI incidence in 
the elderly nearly doubled from 2001 to 2010, significantly outpacing the rise in CDI in 
other age groups.7 In 2017, the U.S. saw a drop in cases and deaths, with 223,900 
hospitalized patients suffering from CDI and 12,800 deaths occurring that year, though C. 
difficile is still seen as a major infectious disease threat with high antibiotic resistance 
potential.12 Recent trends show a consistent reduction of CDI cases by about -4% per 
year from 2011 to 2017,13 equating to an overall CDI reduction of 24%, respectively. 
These trends are credited to the emphasis placed on improved hospital infection control 
practices and subsequent reduction in overall healthcare-associated infections throughout 
this time period, which is further strengthened by trend data showing that healthcare-
associated C. difficile infection decreased by approximately -6% per year (36% decrease 
in total) but there was no statistically significant reduction in community-associated C. 
difficile during the same time period.13 CDI recurrence also continues to be a major 
concern. In 2017, there were approximately 69,800 patients who experienced a first 
recurrence in the U.S. (Table 1.1). The national burden of CDI in the U.S. from 2011 to 











CDI is the main cause of bacterial infectious diarrhea in nosocomial settings,14 but 
the community is a major source of infection as well,15 with sources citing up to 50% of 
total cases in some countries resulting from community-acquired transmission.13,16 CDI is 
categorized into one of three types as defined by the Society of Hospital Epidemiologists 
(SHEA) and Infectious Disease Society of America (IDSA) for surveillance purposes: 1) 
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healthcare facility-onset (HO-CDI), 2) community-onset, healthcare facility-associated 
(CO-HCFA-CDI), and 3) community-associated (CA-CDI). Criteria for meeting these 
definitions are summarized in Table 1.2.  
 
Table 1.2. Surveillance categories of CDI by the CDC Emerging Infections Program.17 
CDI category Clinical definition  
Healthcare facility-onset Positive stool specimen collected greater 
than 3 days after hospital admission OR 




Positive stool specimen collected in 
outpatient setting OR within 3 days after 
hospital admission in any person with 
documented overnight stay in a healthcare 
facility (hx of hospitalization or. LTCF 
residency in previous 12 weeks) 
Community-associated  Positive stool specimen collected in 
outpatient setting or within 3 days in any 
person with no documentation of 
overnight stay in a healthcare facility in 
previous 12 weeks  
 
CDI primarily manifests as diarrhea but can lead to severe manifestations or even 
death. In a national study, Lucado et al. found that patients with CDI experienced 
sepsis/septicemia (26.7%), acute renal failure (23.6%), shock (8.0%), ileus (4.7%), 
perforated intestine (0.4%), and megacolon (0.1%).10 Among hospitalized CDI patients, 
mortality ranges from 14% to 25% at 30 days, 17% to 22% at 60 days, and 23% to 29% at 
90 days following CDI diagnosis.18-25Among critically ill patients, 30-day mortality is 
substantially higher (37%).25,26  
 
 7 
Figure 1.2. Inflammatory response in CDI-induced pseudomembranous colitis of the 
colon27 (left) compared to a healthy colon28 (right) during colonoscopy.  
 
Importantly, patients who experience one CDI episode are likely to experience it 
again. Approximately 25% of CDI patients will suffer a recurrence despite successful 
treatment of the initial episode.29 Furthermore, 45% to 65% of patients who suffer one 
recurrent episode will have additional recurrences.30 Recurrent CDI places a heavy burden 
on patients, as it increases morbidity and mortality, and diminishes quality of life. Patients 
with recurrent CDI experience prolonged symptoms and repeated courses of antibiotics.31 
This can lead to increased risk of adverse effects, re-hospitalization, and potential 
transmission to other vulnerable patients.32 Importantly, CDI has been associated with 
impaired functional capacity in the short-term and poor overall quality of life, including 
physical, mental, and social functioning.32,33 Garey et al. noted that patients with recurrent 
CDI had significantly lower quality of life overall compared to patients with a primary CDI 
episode within 7 days.33 Quality of life scores consistently decreased with number of CDI 
episodes and increased with time since last episode. Finally, in a recent study, we found 
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that hospitalized patients with CDI are more likely to be discharged to a non-home location 
(e.g., nursing home, hospice) compared to non-CDI control patients.34 Despite robust, 
short-term epidemiological studies, the long-term impact of CDI on physical and mental 
functioning has not been investigated. 
 
CDI DIAGNOSIS  
Clinicians can make an initial diagnosis of CDI based on clinical presentation of 
suspected infection, including frequent, new-onset diarrhea (defined as ≥3 loose stools per 
day). Presentation may also include a fever (>102 degrees), abdominal distention, and 
leukocytosis, according to 2017 guidelines.35 Patients with other well-defined CDI risk 
factors should also be considered for further testing, as described in the next section. 
Despite suspicion of infection based on clinical presentation, empiric antibiotic 
therapy without confirmed diagnostic test results is not appropriate, as previous literature 
has shown that only approximately 30% of hospitalized patients experiencing diarrhea have 
CDI.11 This, however, does not apply to patients in rapid deterioration who are at high risk 
for CDI and may benefit from empiric therapy while awaiting diagnostic confirmation.  
Diagnostic testing confirmation can occur through several tests; however, the stool 
test is the current gold standard. Because symptomatic infection cannot occur without the 
presence of toxins, tests should measure the presence of TcdA and TcdB in stool samples, 
which encompasses several assays, depending on the method used. A summary of 
diagnostic testing can be found in Table 1.3. 
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Sensitivity Advantages Disadvantages 
Tissue cytotoxic 
assay  
48 hrs 94 – 100% Gold standard 
 
A, B strains both 
detected 










15-45 min 58 – 92% Easy use  
 









2 hrs  
80 – 99% 
Easy use No distinction 
between toxins 
ELISA 
Toxin A + B 
2 hrs A, B strains both 
detected 
Sensitivity for low-
level toxins is 
increased 
Immunochromat
ographic toxin A 












Endoscopy 2 hrs 51% Pseudomembran
ous colitis 
diagnostic tool 




2 hrs 98-99% Rapid test 
 
Highly sensitive 
Tests for toxin genes, 
which may not 
correlate with 
expression 
*ELISA: enzyme-linked immunosorbent assay 
 10 
CDI RISK FACTORS  
While there are several risk factors for CDI, antibiotic therapies are now widely 
understood to be the most important factor in a patient’s history. As the antibiotics 
disrupt the normal gut microbiome, the risk of C. difficile colonization and resulting 
illness from C. difficile increases. While risk from antibiotics vary based on a number of 
individual factors, studies have shown that the gut microbiome becomes disrupted, 
increasing CDI risk, and can occur from as little as one dose (e.g., those used to prepare 
for surgical procedures).36 It is also understood that longer therapies, multiple agents, and 
particular classes of antibiotics can carry even higher risk for CDI due to increased gut 
microbiome disruption. For example, several antibiotic classes have been identified as 
carrying significant CDI risk; clindamycin, carbapenems, and extended-spectrum 
penicillins and cephalosporins more extensively cause damage to normal, protective gut 
microbiota.11 Antibiotics associated with CDI risk, as well as other medications, host-
related factors, and clinical characteristics and interventions that increase CDI risk are 




Table 1.4. Pharmacologic, host-related, and clinical risk factors associated with CDI.37 
 
Risk Factors 
Pharmacological:  antibiotics Pharmacological: other 
   Clindamycin 
   Carbapenems 
   Cephalosporins (3rd/4th gen.) 
   Fluoroquinolones 
   Penicillins 
   Cephalosporins (1st/2nd gen.) 
   Trimethoprim 
   sulfamethoxazole 
   Macrolides 
   Aminoglycosides 
   Daptomycin 
   Tetracyclines 
   Vancomycin 
Gastric acid suppressants 
   Histamine 2 receptor  
   antagonists  
   Proton pump inhibitors 
Other 
   Chemotherapeutic agents  
   Anti-ulcer medications 
   (non-specific)  
   Non-steroidal 
   anti-inflammatory drugs  
   Corticosteroids  
   Opiates (use during 
   last CDI episode)  
Host-related Clinical characteristics 
   Age >65 years  
   Chronic kidney disease 
   Diabetes mellitus  
   Cancer or malignancy   
   Previous CDI diagnosis 
   Hospital length of stay 
   Nasogastric feeding tube 
   Intensive Care Unit admission 
   Gastrointestinal procedures 
 
Non-antibiotic medications can also cause distinct damage to human gut 
microbiome. First, gastric acid suppressant medications decrease microbial diversity in 
the gut by increasing gastrointestinal pH and inhibiting the growth of beneficial gut 
microbiota. Specifically, proton pump inhibitors interfere with microbial composition by 
restricting bacterial proton pumps, and are therefore suspected to be a greater risk for 
CDI than histamine 2 receptor antagonists in comparison.23 Chemotherapeutic agents, 
nonsteroidal anti-inflammatory drugs, anti-ulcer medications, and corticosteroids are non-
antibiotic medications that may also increase a patient’s risk for CDI development.38 
Opioids have been investigated as a potential risk factor for CDI as well; however, 
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opioids were more strongly associated with the development of severe symptoms and 
complications of CDI, such as toxic megacolon, when taken around the time of the 
episode, as opposed to increasing the risk of developing initial infection.11  
In addition to medications, host-related factors and clinical characteristics or 
interventions can play a role in the development of CDI. Healthcare-related exposures 
and factors that impact host immune response are most influential in these categories, 
including severe underlying illness, older age, and extended hospital or healthcare setting 
exposures, such as prolonged hospital length of stay or residency in a long-term care 
facility. Specifically, each additional day of a hospital stay increases CDI risk.39 All of 
these risk factors should be considered by clinicians when evaluating a patient for 
possible to optimize diagnostics and timely treatment.   
 
CLINICAL PRACTICE AND TREATMENT GUIDELINES 
The primary clinical practice guidelines for CDI have been development and 
continually updated by IDSA/SHEA. Given the span of this sixteen-year retrospective 
study, it is important to review the specific differences in updated treatment guidelines 
over the study period. The practice guidelines for the treatment of CDI in adults 
published in 2010 can be seen summarized in Table 1.5.39 Additionally, the updated 
guidelines, published in 2017, are summarized in Table 1.6.35 
The overarching treatment approach has remained much the same over the past 
two decades. First, clinicians are recommended to discontinue therapy of any inciting 
antimicrobial agents, as this could affect the patient’s risk of developing a recurrent 
infection. Evaluation should include patient age, 24-hour bowel movement count, white 
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blood cell count, and peak serum creatinine level, which will aid in determining the 
severity of the infection and guiding some treatment guidelines, such as candidate status 
for surgery. Patients should also be evaluated for dehydration and rehydrated with oral or 
intravenous rehydration therapies if needed. Finally, antibiotic therapy should be initiated 
following a positive C. difficile stool test or empirically in patients with a high probability 
of CDI based on their risk factors.35  
Antibiotics are the mainstay therapy for CDI. In the 2017 guidelines, oral 
vancomycin or fidaxomicin are strongly recommended to treat the first episode of CDI 
(non-severe and severe). Oral metronidazole is weakly recommended in non-severe CDI 
if oral vancomycin or fidaxomicin are unavailable. Regardless of severity, treatment is 
recommended for ten days. An initial episode of fulminant CDI (CDI with shock, ileus, 
or megacolon) may be treated with oral vancomycin in combination with intravenous 
metronidazole. If oral metronidazole is used for the initial episode of CDI, oral 
vancomycin may be used to treat the first recurrence. Otherwise, a prolonged and tapered 
oral vancomycin regimen or fidaxomicin are recommended for first recurrence CDI. 
Subsequent recurrences may be treated with tapered and pulsed oral vancomycin 
(Vancomycin 125 mg PO 4 times daily for 10-14 days, then 2 times daily for 7 days, then 
daily for 7 days, and then every 2-3 days for 2-8 weeks), oral vancomycin followed by 
oral rifaximin, fidaxomicin, or fecal microbiota transplantation, although the expert panel 
recommends reservation of the fecal transplant for patients suffering at least two 
recurrences. 
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The major updates in the 2017 guidelines compared to the 2010 guidelines 
include the following: 1) metronidazole is no longer recommended first line, 2) 
fidaxomicin is now recommended as a first line option with vancomycin, 3) fecal 
transplant is recommended for patients with more than three CDI episodes, and 4) toxin 
tests are now emphasized as part of laboratory diagnostic algorithms. Metronidazole is no 
longer the recommended first line treatment. 
Table 1.5. Practice guidelines for the treatment of adult CDI 2010. 
 
Clinical appearance  Treatment recommendation 
Initial episode, mild to moderate (non-
severe) 
Metronidazole 500 mg PO 3 times/day for 
10-14 days 
Initial episode, severe Vancomycin 125 mg PO 4 times/day for 
10-14 days  
Initial episode, severe complicated* Vancomycin 500 mg PO (or by rectum if 
ileus if present) 4 times/day and 500 mg 
in approx. 100 mL normal saline per 
rectum every 6 hours as retention enema 
with or without metronidazole 
intravenously every 8 hours 
First recurrence**  Same regimen as patient’s initial episode 
with stratification based on severity as 
stated above. 
Subsequent recurrence(s) Vancomycin therapy with tapered and/or 
pulse regimen 
Patients with continued antimicrobial 
therapy for other underlying infections 
No recommendations can be made for 
prevention of CDI in this population 
*Consider colectomy for severely ill patients; monitor serum lactate levels and peripheral white blood cell 
count for decision making in surgery. Perform subtotal colectomy with preservation of the rectum. 








Table 1.6. Practice guidelines for the treatment of adult CDI 2017 update. 
 
Clinical appearance  Treatment recommendation 
Initial episode, mild to moderate (non-
severe) 
Vancomycin 125 mg PO 4 times/day or 
fidaxomicin 200 mg twice/day for 10 days 
Initial episode, severe* A severe initial episode can be treated with the 
same dosage of vancomycin or fidaxomicin as an 
initial non-severe infection  
Initial episode, severe fulminant** Vancomycin 500 mg 4 times/day PO or NG tube.  
If ileus is present: rectal vancomycin enema (500 
mg in 100 ml normal saline per rectum 4 
times/day) 
Intravenous metronidazole 500 mg, 3 times 
daily can be added with oral or rectal 
vancomycin.  
Surgical intervention† may be required in patients 
w/ fulminant colitis, toxic megacolon, intestinal 
perforation, and/or necrotizing colitis 
First recurrence Prolonged taper and pulsed vancomycin regimen 
of 125 mg PO, 4 times/day for 10 to 14 days, 2 
times/day for 7 days, once/day for 7 days, 
and lastly, once every 2 to 3 days for 2 to 8 weeks 
or fidaxomicin 200 mg PO, 2 times/day 
for 10 days if vancomycin was used for the initial 
episode. 
Subsequent recurrence(s) *** Taper and pulsed vancomycin regimen as 
mentioned for the first recurrence, vancomycin 
125 mg PO, 4 times/day for 10 days followed by 
rifaximin 400 mg PO, 3 times/day for 20 days, 
fidaxomicin 200 mg, 2 times/day for 10 days, OR 
fecal transplantation 
*Severe infection is defined as a white blood cell count greater than 15,000 cells/microL, serum albumin 
less than 3 g/dL, and a serum creatinine level greater than 1.5 times the premorbid level 
**Fulminant infection is defined as infection with the presence of hypotension, shock, ileus, or megacolon 
†Subtotal colectomy with preservation of the rectum 
***Bezlotoxumab has been recently approved for the management of recurrent CDI. Fecal transplantation 
has reported an 80% to 90% success rate in reducing the recurrence of CDI. Expert opinion suggests 




Chapter 2: CDI and the Potential Relationship with Aging-Related 
Conditions  
POST-CDI HEALTH OUTCOMES EXTEND BEYOND THE SHORT-TERM 
CDI likely contributes to poor long-term outcomes and development of aging-
related conditions. Given the substantial burden endured by CDI patients in the short-
term, it is likely that these patients may be at risk for poor long-term outcomes as well. 
The biological mechanism for this relationship may be due to the significant impact CDI 
and antibiotic therapy place on the human gut microbiota. The gut microbiota play an 
important role in maintaining human health (i.e., healthspan), including energy and 
nutrient extraction, host immune system modulation, and protection against pathogens.6 
CDI pathogenesis has been linked to a disruption in the normal gut microbiota (i.e., 
dysbiosis), predominantly following antibiotic exposure. In addition, antibiotics are the 
mainstay therapy for CDI and prior studies have found that recovery of the microbiome 
post-antibiotic use is slow and that some patients never fully restore microbiome 
diversity.40 In the short-term, this increases the risk for CDI recurrence; however, long-
term dysbiosis could increase the risk for several other health conditions. Microbiome 
dysbiosis has been associated with systemic inflammation, a multitude of aging-related 
conditions, and frailty, all of which pose a significant burden on the health of patients and 
the health care system.41 When the microbiome becomes disrupted due to antibiotic 
exposure, CDI, or age-related changes, the functional benefits may be altered. In a 
normal healthy individual, once the stressor is removed, the microbiome is able to fully 
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recover; however, in some individuals, these stressors may permanently deplete essential 
commensal bacteria, preventing full microbiome recovery.42,43 This can ultimately lead to 
poorer health outcomes and decreased healthspan and lifespan, particularly in an elderly 
and aging population. Specifically, studies have found that gut dysbiosis can influence 
the development of several diseases and aging-related conditions.44 
Unhealthy aging as a result of CDI poses a significant problem to patients and the 
healthcare system. Increases in aging-related health problems due to CDI potentially pose 
a significant burden to the healthcare system, especially as the population ages. Age-
related health problems, including bone fractures and dementia, contribute to frailty, 
which is characterized by declines in physiologic reserve and function, resulting in 
increased risk of adverse health outcomes.45 The prevalence of frailty is estimated to be at 
least 10% among community-dwelling U.S. adults, and increases with age.46 The 
associated costs of frailty were estimated to be more than $18 billion in 2000, with a 
continued increase over the next two decades.47 Thus, in the setting of an aging 
population and growing incidence of CDI, an increasingly frail older population will have 
major implications for the demand for health care services, including hospital usage, 
home care, and long-term care. 
Healthspan and lifespan effects of CDI could inform new drug development and 
clinical practice. Prior clinical trials have identified patient-specific factors that increase 
the risk for mortality and recurrent CDI, including advanced age, immunosuppression, 
concomitant use of non-CDI antimicrobial therapy or gastric-acid suppressing drugs, long 
hospital stays, and severity of illness.48,49 Given the association between dysbiosis and 
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aging-related conditions, it is possible that similar factors might affect risk for 
development of aging-related conditions; however, it is unclear the extent to which these 
factors impact these conditions, nor whether certain therapies can mitigate risk. This 
represents a significant knowledge gap in the care for patients with CDI. While certain 
patient factors may not be modifiable (e.g., age), other factors like treatment decisions 
and access to care could be optimized to improve CDI health outcomes and ultimately 
promote healthy aging. For example, fidaxomicin has a narrower spectrum of activity 
compared to vancomycin, with high activity against C. difficile while preserving more of 
the normal gut microbiota. In addition, alteration of the gut microbiota in the setting of 
CDI and aging-related diseases has prompted interest in the use of prebiotics, probiotics, 
and fecal microbiota transplantation (FMT). Prebiotics support the nourishment of the 
normal gut microbiota, while probiotics and FMT aim to restore its microbial diversity 
and structure. Prior studies documented increased diversity and restoration of specific 
bacterial taxa and important metabolites following FMT in patients with C. difficile 
infection,50,51 while safely improving patient outcomes.52 More recently, rationally 
designed combinations of microbes (i.e., Ecobiotics) are being developed to target known 
microbial deficiencies. Other therapies that target the immune response could also serve 
as a potential option during CDI to promote positive long-term outcomes. Immune 
response to C. difficile is a major determinant of health outcomes among patients with 
CDI;53 therefore, immunomodulatory therapies, such as statins, immune globulins, and 
monoclonal antibodies may play a role in reducing the risk of CDI recurrence. Our 
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population-based study will serve to inform treatment decisions to potentially improve 
healthspan and lifespan among patients who develop CDI. 
GUT MICROBIOME DYSBIOSIS AND AGING 
Gastrointestinal microbiome dysbiosis has been linked to a number of aging-
related chronic conditions, including frailty, cancer, and cardiovascular, metabolic, and 
neurological diseases. These conditions place a major burden on patients, caregivers, and 
the healthcare system, including increasing demand for health care services (e.g., hospital 
and long-term care). Given the strong link between dysbiosis and CDI, as well as 
dysbiosis and other aging-related conditions, we hypothesize that CDI will 
accelerate the development of aging-related conditions. Population-based analysis of 
this relationship will ultimately help inform prospective clinical studies to validate this 
association, as well as determine the underlying mechanisms and inform preventive 
interventions. 
The scientific rationale for studying the effects of CDI on healthy aging stems 
from the strong biological connections mediated by gut microbiome dysbiosis and 
inflammation (Figure 2.1), as well as prior supporting epidemiological studies. The 
complexity of the human immune system and the gut microbiome aids in promoting 
healthy aging and, in turn, prevention of disease. The immune system comprises innate 
and adaptive properties which, over time, recognize the commensal bacteria residing in 
our bodies, forming a symbiotic alliance. Although this relationship ultimately protects 
the host from most harm, disruption of the normal gut microbiota can predispose to many 
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diseases. For example, recovery of the microbiome post-antibiotics can take up to 90 
days, with some original taxa not fully recovering to its original composition,40,42,43 
suggesting that a combination of both CDI and antibiotic therapy could create an even 
further devastating, and potentially irreversible effect, on the gut microbiome 
composition. In an aging population, changes to the gut microbiota can increase the risk 
for a number of chronic conditions, including cardiovascular disease, metabolic disease, 
and neurological disorders like Alzheimer’s Disease and Parkinson’s Disease.41 In 
addition, those experiencing a loss of microbial diversity in the distinct core groups of 
bacterial taxa has been associated with reduced cognitive performance and increased 
frailty.54 
 
















Our research team has generated substantial preliminary data for the proposed 
project. We found that the national incidence of CDI among veterans more than tripled 
between 2003 and 2013 (1.6 vs. 5.1 cases/10,000 population). CDI patients were older 
(median age 67 years) and had multiple other comorbidities. We also noted a high rate of 
30-day mortality (21%) and CDI recurrence (17%) in this population.15 We have also 
described the shift from hospital- to community-onset CDI,55 and created a prediction 
model for CDI recurrence among veterans.56 Most recently, we found that hospitalized 
patients with CDI frequently required a higher level of medical care residence (e.g., 
nursing home) at discharge compared to non-CDI patients.34 While we couldn’t ascertain 
the reason for this association, we hypothesize that this could be due to the poor physical 
and mental functioning associated with CDI. CDI patients, especially those with recurrent 
infection, have poor quality of life scores in the short-term, as indicated by the Cdiff32 
survey (Figure 2.2).33 Because of the biological plausibility and preliminary studies, we 
propose that CDI patients will have poorer health at follow-up compared to controls and 
that certain CDI and treatment characteristics will predict healthy aging outcomes among 












To our knowledge, no studies have evaluated the long-term effects of CDI on 
healthy aging, nor identified factors that promote healthy aging in this population. To 
inform this knowledge gap, we propose a series of study aims that seek to address the 
central hypothesis that CDI significantly impacts healthy aging, likely due to its 
influence on the gut microbiome and inflammation, and that certain CDI and patient 
characteristics will be associated with better outcomes among patients who develop CDI. 
Specifically, our overall objective is to test if CDI impacts the development of aging-
related conditions, frailty, and longevity in a national, retrospective cohort of veterans 
with longitudinal follow-up over 16 years. 
The study is innovative because it will be the first study to assess the long-term 
impact of CDI on healthy aging. The study will inform predictors of long-term outcomes 
of CDI and inform potential interventions for healthy aging. The proposed research is 
expected to have a positive impact on human health by promoting the importance of CDI 
prevention and giving consideration to predictors that will guide future treatments to 
decrease the healthcare burden of older adults. Our team plans to use the results of this 
study to support a prospective clinical study of CDI patients to validate study findings, 
determine the biological basis for such associations, and guide future treatment decisions 
for patients with CDI.  
We utilized the largest population to date to study the association between CDI 
and these important outcomes. We assessed approximately 31,513 CDI patients and 
81,293 controls within the Veterans Health Administration (VHA) over a 16-year period. 
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Use of the VHA comprehensive electronic medical record system allowed us to capture 
inpatient and outpatient diagnoses and to follow patients longitudinally, minimizing the 
risk for misclassification. The size of the population also allowed us to run subgroup 
analyses on underrepresented populations, such as women, to enhance generalizability. 
We used robust statistical analyses that reduced the impact of confounding. Importantly, 
our team was able to expertly assess and interpret the clinical significance of a 
statistically significant effect size, given the large sample size. 
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Chapter 3:  Specific Aim and Hypotheses 
SPECIFIC AIM 1: DESCRIBE THE SHORT-TERM HEALTH OUTCOMES OF CDI IN A 
NATIONAL RETROSPECTIVE VETERAN COHORT 
Hypothesis 1.1: CDI patients will experience earlier mortality over 1-, 3-, and 12-
month follow-up periods compared to non-CDI controls 
 
Hypothesis 1.2: CDI patients will experience more aging-related conditions over 
1-, 3-, and 12-month follow-up periods compared to non-CDI controls  
 
Hypothesis 1.3: CDI patients will experience more frailty-associated diagnoses 
over 1-, 3-, and 12-month follow-up periods compared to non-CDI controls 
 
SPECIFIC AIM 2: DEFINE THE LONG-TERM IMPACT OF CDI ON HEALTHY AGING IN A 
NATIONAL RETROSPECTIVE VETERAN COHORT 
Hypothesis 2.1: CDI patients will experience earlier mortality over a 10-year 
follow-up period compared to non-CDI controls 
 
Hypothesis 2.2: CDI patients will experience more aging-related conditions over a 
10-year follow-up period compared to non-CDI controls  
 
Hypothesis 2.3: CDI patients will experience more frailty-associated diagnoses 




Chapter 4:  Research Strategy 
 RESEARCH DESIGN 
This was a retrospective cohort study of all patients receiving care at any of the 
approximately 171 VHA hospitals and 1,283 VHA clinics in the U.S. Data were obtained 
from the VA Informatics and Computing Infrastructure, which includes administrative, 
clinical, laboratory, and pharmacy data repositories which are linked using unique patient 
identifiers. Specifically, the team used four national VA data sources: the VA Medical 
SAS Datasets (both inpatient and outpatient), the VA Vital Status File, the VA Decision 
Support System, and the VHA Annual Enrollment Files. The VA Medical SAS Inpatient 
Dataset includes patient demographics, diagnoses, procedures, hospital length of stay, 
and discharge status. The VA Medical SAS Outpatient Dataset includes patient 
demographics, diagnoses, and procedures. The VA Vital Status File contains date of birth 
and death, and gender for each veteran. The VA DSS integrates data from clinical and 
financial systems to create National Data Extracts (NDEs). NDEs include laboratory 
results and both inpatient and outpatient pharmacy records. Finally, the VHA Annual 
Enrollment Files contain eligibility information that was used to create priority groups. 
All data collection and analyses were performed at the South Texas Veterans Health Care 
System, Audie L. Murphy VA Hospital, San Antonio, TX. 
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Study Population 
All adult VHA beneficiaries (18-89 years old) were eligible for study inclusion. 
The CDI cohort included adult patients who had any inpatient or outpatient visit for CDI 
at the VA from October 1, 2002 to September 30, 2018 (cohort inclusion period). Patients 
eligible for the full 10-year outcome analysis were patients with CDI between October 1, 
2002 and September 30, 2008. CDI was defined as an ICD-9-CM or ICD-10 code for 
CDI (008.45 and A04.72, respectively), plus a positive stool test (e.g., glutamate 
dehydrogenase, toxin enzyme immunoassay, polymerase chain reaction), and active CDI 
therapy during the visit or within 7 days of the visit during the cohort inclusion period. 
To limit survivor bias, we limited the cohort to first CDI episodes only by excluding 
patients with an ICD-9-CM code for CDI in the year prior to cohort inclusion. A control 
group was created by randomly sampling VHA patients without an ICD-9-CM or ICD-
10-CM code for CDI at any time during the study period, group matching to the CDI 
cohort 2:1 based on fiscal year and visit setting (inpatient vs. outpatient).  
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Data extraction and variable creation were conducted using SAS Version 9.4 
(SAS Institute, Cary, NC, USA). Propensity score matching was performed using 
STATA 14 (StataCorp, College Station, TX, USA). All other data and statistical analyses 
were conducted using JMP 14 (SAS Institute, Cary, NC, USA). All variables were 
presented descriptively, with continuous variables presented as means, standard 
deviations, medians, and interquartile ranges as appropriate. Categorical variables were 
presented as the number and percentage of subjects in each category. For baseline 
characteristics (e.g., sex, race, ethnicity, priority group), we included a “missing” 
category. Other variables that were absent from the medical chart (e.g., comorbidities, 
medications) were assumed to have not occurred. For all analyses, we reduced the risk for 
type I error by setting the threshold for statistical significance as p<0.0001 for both 
bivariable and multivariable analyses. 
Study dependent variables 
Study dependent variables included all-cause mortality, aging-related conditions, 
and frailty-associated diagnoses (Table 4.1). The primary outcome was all-cause 
mortality assessed as a dichotomous variable at specific time points (1 month, 3 months, 
12 months, and 10 years) as well as a continuous variable for survival analysis. Time to 
death was defined as the date of death minus the date of cohort inclusion (date of CDI 
diagnosis or matching control visit) during the cohort inclusion period. Secondary 
outcomes included aging-related conditions and frailty-associated diagnoses, which were 
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assessed as dichotomous variables at specific time points (1 month, 3 months, 12 months, 
and 10 years). Aging-related conditions included cardiovascular disease (myocardial 
infarction or stroke), cancer, and neurodegenerative diseases (dementia, Alzheimer’s 
diseases, Parkinson’s disease). These diagnoses were chosen due to their association with 
age and gut microbiome dysbiosis.27 Frailty-associated diagnoses included coagulopathy, 
involuntary weight loss, fluid & electrolyte imbalance, anemia, and fall or fracture. The 
diagnoses were chosen based on literature review and expert opinion, as well as 
supporting evidence from investigators that support the association between frailty-
related diagnoses and hospital readmissions.45 Additionally, we compared the validated 
VHA Frailty Index used in VA hospitals and clinics to determine frailty and fall risk in 
elderly patients. To ensure temporality of the association between CDI and aging- and 
frailty-related health outcomes, we excluded patients who had any of the outcome 





Table 4.1. Summary of study dependent variables. 
Dependent variable Definition 
All-cause mortality Death as indicated in the VA Vital Status File 
Aging-related conditions Indicated by ICD-9 or ICD-10 code below 
    Cardiovascular disease 410, 412, 430-438 (ICD-9) or I21, I63.0-I63.9 (ICD-10) 
    Cancer 140-172, 174-208 (ICD-9) or C&D codes (ICD-10) 
    Neurodegenerative diseases 290, 294, 331-2 (ICD-9) or G20, G30-1, F01-3 (ICD-10) 
Frailty-associated diagnoses Indicated by ICD-9 or ICD-10 code below 
    Coagulopathy 286.0-286.9 (ICD-9) or D65-D69 (ICD-10) 
    Involuntary weight loss 783.21 (ICD-9) or R63.4 (ICD-10) 
    Fluid & electrolyte imbalance 276.9 (ICD-9) or E87 (ICD-10) 
    Anemia 280.0-285.9 (ICD-9) or D60-D64 (ICD-10) 
    Falls V15.88 (ICD-9) or Z91.81 (ICD-10) 
    Fracture 800.0-829.9 (ICD-9) or S02, S22, S32, M48 (ICD-10) 
Study control variables 
A summary of all independent variables is provided in Table 4.2. In brief, patient 
demographics, including sex, race, and Hispanic ethnicity were defined as the most 
frequent reporting of each over the study period to ensure accuracy. Geographic region 
was defined by the VA Integrated Service Network (VISN) in which the patient was seen 
for their study inclusion visit. VHA priority group was included as a marker of 
socioeconomic and disability status. Healthcare exposures in the prior year included 
inpatient and outpatient visits to the VA, chronic dialysis, and long-term care facility 
residence. These variables aid in determining patient acuity and healthy-user bias in each 
cohort. Charlson comorbidities were collected in the year prior to study inclusion and 
during follow-up as defined by Deyo, et al.57 Selim psychiatric comorbidities and other 
relevant diagnoses were also collected, as defined by ICD-9-CM or ICD-10 codes. We 
also evaluated medications likely to increase the risk for CDI, including antibiotics, 
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gastric acid suppressants, opioids, motility agents, and cancer chemotherapy. Given the 
long follow-up period, there are several factors that could impact risk for mortality or 
development of aging-related conditions that should were controlled for in our analysis. 
We evaluated healthcare exposures, comorbidities, and medications over the course of 
the follow-up period. In addition, we included several factors that could impact 
outcomes, including concomitant non-CDI antibiotic use, concomitant infections, and 
severity indicators (Table 4.3). Community-onset CDI (CO-CDI) was defined based upon 
the presence of CDI therapy initiated in the outpatient setting or on days 1 or 2 of 
hospitalization. Community-onset, healthcare facility-associated CDI (CO-HCFA-CDI) 
was defined the same way, with the addition of a hospitalization in the prior 90 days. 
Lastly, healthcare facility-onset CDI was defined as CDI therapy beginning on day 3 or 
later of hospitalization. We also captured number of CDI episodes over the study period 





Table 4.2. Study control variables 
Propensity score covariates Regression & Cox model covariates 
Demographics: 
Age, sex, race, Hispanic ethnicity 
Fiscal year 
Geographic region (VISN) 
VHA priority group & copay status 
Exposures in prior year: 
Inpatient & outpatient visits 
Chronic dialysis 
Long-term care facility 
Medications in prior 90 days: 
Antibiotics 
Gastric acid suppressants 
Laxatives or anti-diarrheals 
Narcotics 
Cancer chemotherapy 
Charlson comorbidities in prior year 
Selim comorbidities in prior year 
Other important comorbidities 
VHA frailty index 
 
Exposures during 10-year follow-up: 
Inpatient & outpatient visits 
Chronic dialysis 
Long-term care facility 
Medications during 10-year follow-up: 
Antibiotics 
Gastric acid suppressants 
Laxatives or anti-diarrheals 
Narcotics 
Cancer chemotherapy 
Charlson comorbidities in 10-year follow-up 
Selim comorbidities in 10-year follow-up 
Severity indicators during encounter 
Concomitant infections during encounter 
CDI antibiotic & adjunctive therapies 
Number of CDI episodes 
CDI type (community- vs. hospital-onset) 
 
Table 4.3. Indicators of severe CDI infection. 
 
CDI severity indicator Clinical definition 
White blood cell count >15×109/L 
Serum creatinine ≥1.5 mg/dL 
Albumin <2.5mg/dL 
Sepsis/septicemia ICD-9-CM: 020.2, 038.0-038.9, 995.91, 995.92 
ICD-10: R65.2X, A41.X 
Shock/septic shock ICD-9-CM: 639.5, 785.52, 785.59  
ICD-10: R57.0, R57.1, R57.8, R57.9, R65.21 
Prolonged ileus ICD-9-CM: 560.1 
ICD-10: K56.0, K56.4, K56.6X, K56.7 
Megacolon ICD-9-CM: 558.2, 564.7 
ICD-10: K52.1, K59.31, K59.30 
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PROPENSITY SCORE MATCHING AND CONDITIONAL LOGISTIC REGRESSION 
CDI and control groups were propensity score-matched based on characteristics at 
cohort inclusion (Table 4.2). We estimated the probability of patients experiencing CDI 
using a logistic regression model with CDI as the dependent variable and the following 
covariates: patient demographics, comorbidities and exposures in prior year, and 
medications in the prior 90 days. For aging and frailty analyses, patients who experienced 
the outcome of interest (i.e., those with pre-existing conditions) and those who died prior 
to the follow-up period were excluded from the sample. We then matched CDI patients to 
non-CDI controls 1:1 within a propensity score maximum caliper of 0.01. This small 
caliper aimed to tightly match cohorts, while limiting the sample size such that the 
analyses would not be substantially over-powered. Following propensity score matching, 
a series of multivariable logistic regression models were used to compare dichotomized 
study dependent variables between CDI and non-CDI control groups at various time 
points (1 month, 3 months, 12 months, and 10 years) using the covariates in Table 4.2. 
Dependent variables were also defined as continuous variables for time-to-event 
analyses. The variables were then be assessed using a Cox proportional hazard model 
with covariates as described above. For each model, independent variables were 
considered significant predictors of each dependent variable if p<0.0001. Data were 
presented as adjusted odds ratios and 99% confidence intervals. 
 
SUBGROUP ANALYSES 
Given that the VHA population is mostly male (97%), we conducted a subgroup 
analysis in females only. For this analysis, we repeated the propensity score matching and 
conditional logistic regression modeling techniques as described above in female patients 
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only. We also performed subgroup analyses on patients with community-onset CDI (CO-
HCFA-CDI and CA-CDI), as CDI type could substantially impact survivor bias. 
Power and Sample Size 
In our prior work, we built a national cohort of veterans that included 26,149 CDI 
patients and 59,309 control patients from fiscal year 2003 to 2014. In this study, we 
extended the cohort inclusion dates to fiscal year 2018. Given this extension, we have 
31,513 CDI patients and 81,293 controls. For the analyses that will require 10-year 
follow-up, we have 8,521 CDI patients and 21,302 controls available for complete 
follow-up. We conducted a power calculation for our primary outcome of all-cause 90-
day mortality. From preliminary analyses in the unmatched cohorts, approximately 
21.7% of CDI patients and 2.2% of controls experienced 90-day mortality. Using a p-
value of 0.0001, we will achieve near 100% power for this comparison; however, the 
sample size is expected to decrease following matching. For 10-year mortality, we 
approximate that 72.8% of CDI patients and 29.0% of controls will experience mortality. 
Using a p-value of 0.0001, we will achieve near 100% power for this comparison though 
similar sample size reductions will be seen post-matching. We acknowledge that this 
large sample size might result in statistically significant differences between groups even 
with a small effect size. Because of this, we reduced the p-value cutoff for statistical 




Responsible and Ethical Conduct  
The research conducted in this study does not contain human or animal subjects 
and only involves work with de-identified secondary sources of human medical 
information. This retrospective cohort study was conducted in accordance with the ethics, 
regulations, and governing medical practice in accordance with current, acceptable 
techniques and expertise in the United States. The research protocol was dually reviewed 
and approved by the Institutional Review Boards (IRBs) at the South Texas Veterans 
Health Care System and the University of Texas Health San Antonio campus (approval # 
HSC20130473H), per current practice as part of the dual-campus research agreement. 
Subject informed consent is not applicable to this retrospective cohort study and 
was therefore allotted an IRB waiver for the informed consent requirement. Additionally, 
this research involves the use of existing data only, and no healthcare providers or patients 
were contacted at any point during the study period. Data used for this research is currently 
maintained on VA research servers in directories with limited access behind the VA 
firewall system, making a data breach unlikely to occur. Any research personnel with 
access to this data must maintain up-to-date training regarding knowledge and practice of 
stable security processes. Data collection and analysis were performed only by those with 
VHA appointments, therefore, only those with qualified VHA access would and will have 
any access to patient identifying information for the purpose of merging data. No data in 




Chapter 5:  Results 
 BASELINE CHARACTERISTICS 
A total of 40,643 patients met inclusion for the CDI cohort based on the presence 
of a CDI diagnosis code and positive stool test. From this cohort, 446 were excluded for a 
diagnosis of CDI in the previous year and 8,684 were excluded for lack of documented 
CDI active antibiotic therapy, leaving 31,513 CDI patients for analyses. A total of 81,293 
patients met the study inclusion criteria for non-CDI controls, for a total of 112,806 patients 
in the combined CDI and control cohorts. Baseline characteristics for this unmatched study 
population are summarized in Table 5.1. 
CDI patients were predominantly elderly (median age 67 years), white (75.3%) 
males (95.4%) with a median (IQR) Charlson comorbidity score of 2 (1-4). The most 
common Charlson comorbidities for CDI patients in the prior year included: diabetes 
without (37.4%) or with (17.1%) complications, COPD (34.7%), cancer (25.3%), and renal 
disease (23.4%). Other comorbidities were also prevalent among CDI patients, including 
hypertension (72.0%), IBD (29.4%), GERD (26.4%), and depression (24.4%). CDI 
patients were also commonly exposed to medications known to impact CDI development 
risk in the 90 days preceding the index CDI diagnosis, including antibiotics (52.8%) and 
gastric acid suppressants (53.8%).  
In these unmatched cohorts, CDI and control patients significantly differed in 
nearly all variables assessed. CDI patients more frequently had healthcare exposures 
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(outpatient/inpatient visits, dialysis, LTCF residence), medications exposures in the 
previous 90 days, and comorbidities documented in the previous year (Table 5.1). 
 
Table 5.1. Patient baseline characteristics of unmatched cohorts 














   2003 
   2004 
   2005 
   2006 
   2007 
   2008 
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   2012 
   2013 
   2014 
   2015 
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   2017 



















































7548 (9.3%)  
0.1350 
Age* 63 (54-71)   67 (60-78) 61 (53-69)  <0.0001  
Sex 
   Female 












   White   
   Black 
  Other 




















Table 5.1, cont. 
Ethnicity 
   Hispanic 
   Not Hispanic 















   Inpatient 











VHA priority group 
   Group 1 
   Group 2 
   Group 3 
   Group 4 
   Group 5 
   Group 6 
   Group 7 































   VISN 1  
   VISN 2  
   VISN 4 
   VISN 5  
   VISN 6  
   VISN 7 
   VISN 8  
   VISN 9  
   VISN 10  
   VISN 12  
   VISN 15  
   VISN 16  
   VISN 17  
   VISN 19  
   VISN 20  
   VISN 21  
   VISN 22 



























































Exposures in prior year 
  Inpatient visits* 
  Outpatient visits* 
  Chronic Dialysis 






















Table 5.1, cont. 
Medications in prior 90 
days 
  Antibiotics 
  Gastric acid suppressants 
  Laxatives 
  Anti-diarrheals 
  Opioids 































Charlson comorbidities in 
prior year 
   Myocardial infarction 
   Congestive heart failure 
   Peripheral vascular 
disease 
   Cerebrovascular disease 
   Dementia 
   Chronic pulmonary 
disease 
   Rheumatic disease 
   Peptic ulcer disease 
   Mild liver disease 
   Diabetes w/o 
complications 
   Diabetes w/ 
complications 
   Hemiplegia or paraplegia 
   Renal disease 
   Cancer 
   Cancer metastasis 
   Moderate/severe liver 
   Disease 









































































































Table 5.1, cont. 
Selim comorbidities in 
prior year 
   Schizophrenia 
   Depression 
   Bipolar disorder 
   Anxiety disorder 
   Post-traumatic stress 
   disorder 





















 13982 (17.2%) 
5230 (6.4%) 











Other comorbidities in 
prior year 
   Hypertension 
   Dyslipidemia 
   Obesity 
   GERD 
   Transplant 
   IBD 






































 *Median (IQR), IQR = interquartile range 
**VISN= Veterans Integrated Services Network. Locations: VISN 1 (Maine, Vermont, New Hampshire, 
Massachusetts, Connecticut, Rhode Island), VISN 2 (New York, New Jersey), VISN 4 (Pennsylvania, 
Delaware, New Jersey, Ohio), VISN 5 (Maryland, West Virginia, Virginia, Kentucky, Washington D.C.) , 
VISN 6 (North Carolina, Virginia) , VISN 7 (South Carolina, Georgia, Alabama), VISN 8 (Florida), VISN 9 
(Kentucky, Tennessee), VISN 10 (Michigan, Indiana, Ohio, Kentucky, VISN 12 (Wisconsin, Illinois, 
Indiana, Michigan), VISN 15 (Kansas, Missouri, Illinois, Indiana, Kentucky), VISN 16 (Arkansas, 
Mississippi, Louisiana), VISN 17 (Texas), VISN 19 (Montana, Wyoming, Colorado, Utah, Oklahoma, 
Nevada), VISN 20 (Washington, Oregon, Idaho, Alaska, Montana, VISN 21 (California, Nevada, Hawaii, 
Philippines Islands, Guam, American Samoa), VISN 22 (Arizona, New Mexico, California, Nevada), VISN 




Results of specific aim 1: Describe the short-term health outcomes of CDI in a 
national retrospective veteran cohort  
Hypothesis 1.1: CDI patients will experience earlier mortality over 1-, 3-, and 12-month 
follow-up periods compared to non-CDI controls 
 
After assessment of baseline characteristics, the CDI and control cohorts were 
propensity score matched based on factors that may have influenced CDI risk, including 
fiscal year, encounter setting, patient demographics (age, sex, race, ethnicity, VISN, 
priority group), comorbidities (Charlson, Selim, and other) in the year prior to the index 
encounter, healthcare exposures in the prior year (inpatient/outpatient visits, dialysis, 
LTCF residence), medication exposures (antibiotics, GAS medications, opioids, motility 
agents, and cancer chemotherapy) in the prior 90 days, and baseline VHA frailty index. 
Following matching, the distribution of these characteristics between cohorts was well-
balanced (Table 5.2), though some remained statistically significantly different between 









Table 5.2. Patient baseline characteristics of matched cohorts for mortality. 














   2003 
   2004 
   2005 
   2006 
   2007 
   2008 
   2009 
   2010 
   2011 
   2012 
   2013 
   2014 
   2015 
   2016 
   2017 





















































Age* 65 (58 - 75) 65 (58 - 75) 65 (58 - 74) 0.4093  
Sex 
   Female 












   White   
    Black 
   Other 


















   Hispanic 
   Not Hispanic 















   Inpatient 












Table 5.2, cont. 
 
VHA priority group 
   Group 1 
   Group 2 
   Group 3 
   Group 4 
   Group 5 
   Group 6 
   Group 7 





























Geographic region (VISN)** 
   VISN 1  
   VISN 2  
   VISN 4 
   VISN 5  
   VISN 6  
   VISN 7 
   VISN 8  
   VISN 9  
   VISN 10  
   VISN 12  
   VISN 15  
   VISN 16  
   VISN 17  
   VISN 19  
   VISN 20  
   VISN 21  
   VISN 22 



























































Exposures in prior year 
  Inpatient visits* 
  Outpatient visits* 
  Chronic Dialysis 
  Long-term care facility 
 
0 (0-1) 



























Table 5.2, cont. 
 
Medications in prior 90 days 
  Antibiotics 
  Gastric acid suppressants 
  Laxatives 
  Anti-diarrheals 
  Opioids 





























Charlson comorbidities in prior 
year 
   Myocardial infarction 
   Congestive heart failure 
   Peripheral vascular disease 
   Cerebrovascular disease 
   Dementia 
   Chronic pulmonary disease 
   Rheumatic disease 
   Peptic ulcer disease 
   Mild liver disease 
   Diabetes w/o complications 
   Diabetes w/ complications 
   Hemiplegia or paraplegia 
   Renal disease 
   Cancer 
   Cancer metastasis 
   Moderate/severe liver 
   Disease 




























































































Table 5.2, cont. 
 
Selim comorbidities in prior 
year 
   Schizophrenia 
   Depression 
   Bipolar disorder 
   Anxiety disorder 
   Post-traumatic stress 
   disorder 

































Other comorbidities in prior 
year 
   Hypertension 
   Dyslipidemia 
   Obesity 
   GERD 
   Transplant 
   IBD 









































Our primary outcome, all-cause mortality, was assessed at 1-, 3-, and 12-month 
intervals. A total of 29,872 (14,936 CDI and 14,936 non-CDI controls) patients were 
available for all-cause mortality analyses. Mortality was common among CDI patients; at 
12 months, more than a quarter (27.7%) of CDI patients had died compared to only 7.6% 
among controls. Mortality risk was significantly higher in the CDI cohort for all three short-
term follow-up periods (adjusted OR, 99% CI): 1 month (3.75, 3.23-4.34), 3 months (3.07, 
2.74-3.43), and 12 months (2.70, 2.47-2.96) (Table 5.3). The absolute mortality risk 
difference between cohorts increased over time, but after adjustment for covariates, the 
relative risk of mortality between cohorts decreased over time. Other significant predictors 
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of mortality at 12 months included: metastatic cancer (OR 4.43, 99% CI 3.81-5.14), 
moderate/severe liver disease (OR 2.50, 99% CI 1.99-3.13), concomitant pneumonia (OR 
1.78, 99% CI 1.64-1.94), shock (OR 1.36, 99% CI 1.14-1.61), and acute renal failure (OR 











P-value OR (99% CI) Adjusted OR 
(99% CI)a 
1 month 1942 (13.0%) 308 (2.1%) <0.0001 7.09 (6.28, 8.02) 3.75 (3.23-4.34)b 
3 months 2686 (17.9%) 555 (3.7%) <0.0001 5.68 (5.17, 6.24) 3.07 (2.74-3.43)b 
12 months 4136 (27.7%) 1131 (7.6%) <0.0001 4.67 (5.17, 6.24) 2.70 (2.47-2.96)b 
a1 month and 3 month covariates included: bacteremia, pneumonia, skin infection, endocarditis, UTI, device 
infection, ART, shock, sepsis, perforated intestine, ileus, megacolon, acute renal failure, concomitant 
antibiotics, concomitant gastric acid suppressants, WBC, CRP, albumin, SCr, concomitant opioids, 
concomitant anti-diarrheals, concomitant laxatives, ICU stay, hospital length of stay. 12 month covariates 
included 1 and 3 month covariates plus the following assessed during 12 months of follow-up: hypertension, 
dyslipidemia, irritable bowel disease, irritable bowel syndrome, obesity, GERD, transplant, schizophrenia, 
depression, bipolar, anxiety, PTSD, alcohol abuse, CHF, peripheral vascular disease, COPD, rheumatic 
disease, any liver disease, diabetes w/ and w/o complications, hemi/paraplegia, HIV/AIDS, any antibiotics 




Survival analysis was performed and is presented using Kaplan Meier curves in 
Figures 5.1, 5.2, and 5.3, excluding patients who died during the encounter (0 days to 
death). In univariate analysis using the log-rank test, mortality was significantly higher 
among CDI patients (p<0.0001). Using a Cox proportional hazards model that included 
covariates, CDI significantly predicted mortality at 1 month, 3 months, and 12 months 




Figure 5.1. Kaplan Meier survival curve for mortality at 1 month 
 
 









Hypothesis 1.2: CDI patients will experience more aging-related conditions over 1-, 3-, 
and 12-month follow-up periods compared to non-CDI controls. 
  
         For analyses of aging-related condition outcomes during follow-up, we excluded 
a total of 33,883 (30.0%) patients from the unmatched cohorts (13,681 CDI and 20,202 
controls) who had aging-related conditions at baseline. The cohorts were then propensity 
score matched similarly as described for mortality analyses. Following matching, there 
were a total of 9,475 patients in each group (18,950 patients total) for analyses. CDI and 
control patients were well-matched in regard to baseline demographics, prior healthcare 
exposures, prior medication exposures, and prior comorbidities (Table 5.4). 
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Table 5.4. Patient baseline characteristics of matched cohorts for aging-related 
conditions. 















   2004 
   2005 
   2006 
   2007 
   2008 
   2009 
   2010 
   2011 
   2012 
   2013 
   2014 
   2015 
   2016 
   2017 





















































Age* 63 (55-72) 63 (55-72) 63 (55-71) 0.0896 
Sex 
   Female 












   White   
    Black 
   Other 


















   Hispanic 
   Not Hispanic 

















Table 5.4, cont. 
 
Setting 
   Inpatient 











VHA priority group 
   Group 1 
   Group 2 
   Group 3 
   Group 4 
   Group 5 
   Group 6 
   Group 7 





























Geographic region (VISN)** 
   VISN 1  
   VISN 2  
   VISN 4 
   VISN 5  
   VISN 6  
   VISN 7 
   VISN 8  
   VISN 9  
   VISN 10  
   VISN 12  
   VISN 15  
   VISN 16  
   VISN 17  
   VISN 19  
   VISN 20  
   VISN 21  
   VISN 22 



























































Exposures in prior year 
  Inpatient visits* 
  Outpatient visits* 
  Chronic Dialysis 

























Table 5.4, cont. 
 
Medications in prior 90 days 
  Antibiotics 
  Gastric acid suppressants 
  Laxatives 
  Anti-diarrheals 
  Opioids 






























Charlson comorbidities in prior year 
   Myocardial infarction 
   Congestive heart failure 
   Peripheral vascular disease 
   Cerebrovascular disease 
   Dementia 
   Chronic pulmonary disease 
   Rheumatic disease 
   Peptic ulcer disease 
   Mild liver disease 
   Diabetes w/o complications 
   Diabetes w/ complications 
   Hemiplegia or paraplegia 
   Renal disease 
   Cancer 
   Cancer metastasis 
   Moderate/severe liver 
   Disease 













































































Charlson comorbidity score*  



















Table 5.4, cont. 
 
Selim comorbidities in 
prior year 
   Schizophrenia 
   Depression 
   Bipolar disorder 
   Anxiety disorder 
   Post-traumatic stress 
   disorder 


































Other comorbidities in 
prior year 
   Hypertension 
   Dyslipidemia 
   Obesity 
   GERD 
   Transplant 
   IBD 









































At 1 month, 3 months, and 12 months post-index encounter, there were no 
significant differences in the development of aging-related conditions in CDI patients 
compared to controls in bivariable analyses using a p-value cutoff of <0.0001 (Table 5.5). 
Aging-related conditions were numerically higher in the CDI cohort at 1 month and 3 
months, but then numerically higher among controls at 12 months. At 12-months, only 
cancer and neurodegenerative disease were higher in proportions of CDI patients 
compared to non-CDI controls; however, these differences were not statistically 
significant (Table 5.5). In the regression model, CDI was an independent predictor of a 
cancer diagnosis at 1 month follow up (OR 1.27, 99% CI 1.03-1.57), though it was not a 
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predictor at later follow up of 3 and 12 months, which will be discussed further in the 
next chapter (Table 5.5). Other significant predictors of aging-related conditions at 12-
months included: hypertension at 1 year (OR 1.86, 99% CI 1.64-2.11), peripheral 
vascular disease at 1 year (OR 1.48, 99% CI 1.31-1.67), and ICU admission during the 
index encounter (OR 1.31, 99% CI 1.16-1.49). Among CDI patients only, there was no 
significant association between the number of CDI episodes and the development of 
aging-related conditions at 12 months (p=0.2078). 
 
Table 5.5. Prevalence of aging-related conditions at follow-up in matched cohorts 
 




OR (99% CI) Adjusted OR 
(99% CI)a 
1 month n=8432 n=9363 
 
Any aging condition 576 (6.8%) 521 (5.6%) 0.0005 1.24 (1.10-1.41) 0.82 (0.70-0.96)b 
Cardiovascular disease 231 (2.7%) 222 (2.4%) 0.1194 1.16 (0.96-1.39) 0.84 (0.67-1.07) 
Cancer 297 (3.5%) 251 (2.7%) 0.0021 1.26 (1.09-1.47) 1.27 (1.03-1.57)b 
Neurodegenerative 
disease 
83 (0.9%) 64 (0.7%) 0.0269 1.44 (1.04-2.00) 0.83 (0.56-1.23) 
3 months n=8059 n=9275 
 
Any aging condition 801 (9.9%) 852 (9.2%) 0.0924 1.09 (0.99-1.21) 0.79 (0.69-0.90)b 
Cardiovascular disease 321 (4.0%) 404 (4.4%) 0.2210 0.91 (0.78-1.06) 0.68 (0.56-0.82)c 
Cancer 398 (4.9%) 388 (4.2%) 0.0173 1.19 (1.03-1.37) 0.81 (0.68-0.97)b 
Neurodegenerative 
disease 
140 (1.7%) 113 (1.2%) 0.0046 1.43 (1.12-1.84) 1.31 (0.97-1.78) 
12 months n=7293 n=9011 
 
Any aging condition 1135 (15.6%) 1470 (16.3%) 0.1931 0.95 (0.87-1.03) 0.99 (0.89-1.11) 
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Table 5.5, cont. 
 
Cardiovascular disease 565 (7.7%) 821 (9.1%) 0.0018 0.84 (0.75-0.94) 0.96 (0.83-1.12) 
Cancer 458 (6.3%) 530 (5.9%) 0.2897 1.07 (0.94-1.22) 1.01 (0.86-1.20) 
Neurodegenerative 
disease 
240 (3.3%) 261 (2.9%) 0.1476 1.14 (0.95-1.36) 1.21 (0.96-1.52) 
a1 month and 3 month covariates included: bacteremia, pneumonia, skin infection, endocarditis, UTI, device 
infection, ART, shock, sepsis, perforated intestine, ileus, megacolon, acute renal failure, concomitant 
antibiotics, concomitant gastric acid suppressants, WBC, CRP, albumin, SCr, concomitant opioids, 
concomitant anti-diarrheals, concomitant laxatives, ICU stay, hospital length of stay. 12 month covariates 
included 1 and 3 month covariates plus the following assessed during 12 months of follow-up: hypertension, 
dyslipidemia, irritable bowel disease, irritable bowel syndrome, obesity, GERD, transplant, schizophrenia, 
depression, bipolar, anxiety, PTSD, alcohol abuse, CHF, peripheral vascular disease, COPD, rheumatic 
disease, any liver disease, diabetes w/ and w/o complications, hemi/paraplegia, HIV/AIDS, any antibiotics 





Hypothesis 1.3: CDI patients will experience more frailty-associated diagnoses over 1-, 3-
, and twelve-month follow-up periods compared to non-CDI controls 
 
For analyses of frailty-associated condition outcomes during follow-up, we 
excluded a total of 32,771 (29.05%) patients from the unmatched cohorts (14,335 CDI and 
18,436 controls) who had frailty-associated conditions at baseline. Following propensity 
score matching, there were a total of 9,499 patients in each group (18,998 patients total) 
for analyses. CDI and control patients were well-matched in regard to baseline 
demographics, prior healthcare exposures, prior medication exposures, and prior 




Table 5.6. Patient baseline characteristics of matched cohorts for frailty-associated 
conditions 















   2003 
   2004 
   2005 
   2006 
   2007 
   2008 
   2009 
   2010 
   2011 
   2012 
   2013 
   2014 
   2015 
   2016 
   2017 





















































Age* 65 (57-73) 65 (57-74) 64 (56-72) 0.0015  
Sex 
   Female 












   White   
    Black 
  Other 


















   Hispanic 
   Not Hispanic 


















Table 5.6, cont. 
 
Setting 
   Inpatient 











VHA priority group 
   Group 1 
   Group 2 
   Group 3 
   Group 4 
   Group 5 
   Group 6 
   Group 7 































   VISN 1  
   VISN 2  
   VISN 4 
   VISN 5  
   VISN 6  
   VISN 7 
   VISN 8  
   VISN 9  
   VISN 10  
   VISN 12  
   VISN 15  
   VISN 16  
   VISN 17  
   VISN 19  
   VISN 20  
   VISN 21  
   VISN 22 



























































Exposures in prior year 
  Inpatient visits* 
  Outpatient visits* 
  Chronic Dialysis 
























Table 5.6, cont. 
 
Medications in prior 90 
days 
  Antibiotics 
  Gastric acid suppressants 
  Laxatives 
  Anti-diarrheals 
  Opioids 

































Charlson comorbidities in 
prior year 
   Myocardial infarction 
   Congestive heart failure 
   Peripheral vascular disease 
   Cerebrovascular disease 
   Dementia 
   Chronic pulmonary disease 
   Rheumatic disease 
   Peptic ulcer disease 
   Mild liver disease 
   Diabetes w/o complications 
   Diabetes w/ complications 
   Hemiplegia or paraplegia 
   Renal disease 
   Cancer 
   Cancer metastasis 
   Moderate/severe liver 
   disease 















































































score, median (IQR) 












Table 5.6, cont. 
 
Selim comorbidities in prior 
year 
   Schizophrenia 
   Depression 
   Bipolar disorder 
   Anxiety disorder 
   Post-traumatic stress 
   disorder 

































Other comorbidities in 
prior year 
   Hypertension 
   Dyslipidemia 
   Obesity 
   GERD 
   Transplant 
   IBD 











































In bivariable analyses, CDI patients were more likely to experience any frailty-
related condition at 1 month (8.6% vs. 6.2%, p<0.0001), 3 months (15.1% vs. 11.2%, 
p<0.0001), and 12 months (26.8% vs. 23.5%, p<0.0001) (Table 5.7). These differences 
were driven primarily by a higher prevalence of involuntary weight loss and anemia in 
CDI patients at follow-up compared to controls. After adjustment for covariates at 12 
months, CDI was significantly associated with the development of frailty-associated 
conditions (OR 1.27, 99% CI 1.15-1.41) (Table 5.7). Specifically, CDI was significantly 
associated with the development of coagulopathy (OR 1.84, 99% CI 1.33-2.54) and 
weight loss (OR 1.42, 99% CI 1.14-1.77) at 12 months.  Other significant predictors of 
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frailty-associated conditions at 12-months included: dialysis at 1 year (OR 2.41, 99% CI 
1.78-3.26), moderate/severe liver disease (OR 2.32, 99% CI 1.69-3.20), renal disease at 1 
year (OR 1.75, 99% CI 1.54-1.99), cancer at 1 year (OR 1.43, 99% CI 1.28-1.59), 
laxative use at 1 year (OR 1.46, 99% CI 1.31-1.62), and LTFC residence at 1 year (OR 














1 month n=8387 n=9350 
 












Fluid & electrolyte 
imbalance 
















3 months n=8015 n=9241 
 
















Fluid & electrolyte 
imbalance 
















Table 5.7, cont. 
 




12 months n=7203 n=9013 
 
















Fluid & electrolyte 
imbalance 




















a1 month and 3 month covariates included: bacteremia, pneumonia, skin infection, endocarditis, UTI, device 
infection, ART, shock, sepsis, perforated intestine, ileus, megacolon, acute renal failure, concomitant 
antibiotics, concomitant gastric acid suppressants, WBC, CRP, albumin, SCr, concomitant opioids, 
concomitant anti-diarrheals, concomitant laxatives, ICU stay, hospital length of stay. 12 month covariates 
included 1 and 3 month covariates plus the following assessed during 12 months of follow-up: hypertension, 
dyslipidemia, irritable bowel disease, irritable bowel syndrome, obesity, GERD, transplant, schizophrenia, 
depression, bipolar, anxiety, PTSD, alcohol abuse, myocardial infarction, CHF, peripheral vascular disease, 
cerebral vascular disease, dementia, COPD, rheumatic disease, any liver disease, diabetes w/ and w/o 
complications, hemi/paraplegia, HIV/AIDS, any antibiotics (including high risk), in/outpatient visits, 




Next, we calculated the median VA frailty index score for each cohort at each 
follow-up period after excluding those who died at each follow-up period. The median 
frailty index was the same in each cohort at 1 month (0.032) and 3 months (0.065), but then 
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was lower among CDI patients compared to controls at 12 months (0.097 vs. 0.129, 
p<0.0001) and 10 years (0.194 vs. 0.258, p<0.0001) (Figure 5.4).  
 
Figure 5.4. Median VA frailty index over time among surviving CDI and non-CDI patients 
 
 
Additionally, we evaluated the association between baseline VA frailty index and 
mortality in both cohorts using the original unmatched cohorts. Median baseline VA frailty 
index was significantly higher among those who died within 30 days compared to those 
who did not (0.161 vs. 0.113, p<0.0001). Similar findings were seen for those who died 
within 90 days (0.161 vs. 0.097, p<0.0001), and 12 months (0.161 vs. 0.097, p<0.0001).  
 Finally, to determine the potential “dose-response” relationship between CDI and 
frailty, we assessed the correlation between the number of CDI episodes during follow-up 
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at 12 months and the VA frailty index at 12 months. Number of CDI episodes was 
positively and significantly correlated with VA frailty index (p<0.0001), though little of 
the variability in the VA frailty index could be attributed to the number of CDI episodes 
(R2=0.0250) (Figure 5.5). We also assessed the relationship between the number of CDI 
episodes and the development of any frailty-associated condition at 1 year and found a 
significant positive association (p<0.0001).  
 




SPECIFIC AIM 2: DEFINE THE LONG-TERM IMPACT OF CDI ON HEALTHY AGING 
IN A NATIONAL RETROSPECTIVE VETERAN COHORT 
Hypothesis 2.1: CDI patients will experience earlier mortality over a 10-year follow-up 
period compared to non-CDI controls 
 For analyses of long-term health outcomes, all-cause mortality, aging-related 
conditions, and frailty-associated conditions were assessed at a 10-year follow up for all 
patients who had ten years of data available (i.e., those with an index encounter between 
fiscal year 2003 and 2008). To assess all-cause mortality at ten years, we excluded a total 
of 23,106 (77.4%) patients from the unmatched cohorts (11,472 CDI and 11,634 controls) 
who did not have ten years of follow up (excluded patients after 2008 fiscal year). 
Following propensity score matching, there were a total of 3,464 CDI patients and 3,302 
control patients (6,766 patients total) for analyses. CDI and control patients were well-
matched in regard to baseline demographics, prior healthcare exposures, prior medication 
exposures, and prior comorbidities. 
 All-cause mortality was statistically higher among CDI patients at the 10-year 
follow up when compared to non-CDI controls (69.1% vs. 40.6%, p<0.0001). Risk of 
mortality at 10-year follow up was 1.62 times higher in those with CDI after adjusting for 
covariates (Table 5.8). A 10-year survival analysis was performed for all-cause mortality, 
excluding patients who died during the encounter (0 days to death), and shows a 
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statistically significant difference in time (days) to death in CDI patients compared to non-
CDI controls (p<0.0001) (Figure 5.6). 






P-value OR (99% CI) Adjusted OR 
(99% CI)a 
Mortality 2394 (69.1%) 1339 (40.6%) <0.0001 3.28 (2.97-3.63) 1.62 (1.34-1.97)b 
a10 year covariates included: bacteremia, pneumonia, skin infection, endocarditis, UTI, device infection, 
ART, shock, sepsis, perforated intestine, ileus, megacolon, acute renal failure, concomitant antibiotics, 
concomitant gastric acid suppressants, WBC, CRP, albumin, SCr, concomitant opioids, concomitant anti-
diarrheals, concomitant laxatives, ICU stay, hospital length of stay and the following assessed during 10 
years of follow-up: hypertension, dyslipidemia, irritable bowel disease, irritable bowel syndrome, obesity, 
GERD, transplant, schizophrenia, depression, bipolar, anxiety, PTSD, alcohol abuse, myocardial infarction, 
CHF, peripheral vascular disease, cerebral vascular disease, dementia, COPD, rheumatic disease, any liver 
disease, diabetes w/ and w/o complications, hemi/paraplegia, HIV/AIDS, any antibiotics (including high 
risk), in/outpatient visits, dialysis, LTCF stay. 
bp<0.0001 
 




Hypothesis 2.2: CDI patients will experience more aging-related conditions over a 10-year 
follow-up period compared to non-CDI controls 
For 10-year aging-related condition analyses, we excluded a total of 14,698 patients 
without 10-year follow-up and an additional 2,078 patients who died within that 10-year 
period leaving 2,174 patients (794 CDI and 1,380 control patients) for analyses. At 10 
years, CDI patients had numerically fewer aging-related condition (40.3% vs. 52.3%, 
p<0.0001) though this comparison did not remain significantly different after adjustment 
for covariates (OR 1.13, 99% CI 0.52-2.46) (Table 5.9). Individual aging-related conditions 
were each numerically lower in the CDI cohort, though none reached statistical 
significance after adjustment for covariates. Other significant predictors of aging-related 
conditions at 10 years included: hypertension at 10 years (OR 2.30, 99% CI 1.64-3.23) and 
peripheral vascular diseases (OR 2.00, 99% CI 1.58-2.54). Among CDI patients only, the 
number of CDI episodes and the development of aging-related conditions at 10 year were 



































a10 year covariates included: bacteremia, pneumonia, skin infection, endocarditis, UTI, device infection, 
ART, shock, sepsis, perforated intestine, ileus, megacolon, acute renal failure, concomitant antibiotics, 
concomitant gastric acid suppressants, WBC, CRP, albumin, SCr, concomitant opioids, concomitant anti-
diarrheals, concomitant laxatives, ICU stay, hospital length of stay and the following assessed during 10 
years of follow-up: hypertension, dyslipidemia, irritable bowel disease, irritable bowel syndrome, obesity, 
GERD, transplant, schizophrenia, depression, bipolar, anxiety, PTSD, alcohol abuse, CHF, peripheral 
vascular disease, COPD, rheumatic disease, any liver disease, diabetes w/ and w/o complications, 




Hypothesis 2.3: CDI patients will experience more frailty-associated diagnoses over a 10-
year follow-up period compared to non-CDI controls 
For 10-year frailty-associated condition analyses, we excluded a total of 14,569 
patients without 10-year follow-up and an additional 2,247 patients who died within that 
10-year period leaving 2,182 patients (761 CDI and 1,421 control patients) for analyses. 
At 10 years, CDI patients had numerically fewer aging-related condition (55.5% vs. 70.4%, 
p<0.0001) though this comparison did not remain significantly different after adjustment 
for covariates (OR 1.22, 99% CI 0.87-1.72) (Table 5.10). Most individual frailty-associated 
conditions were each numerically lower in the CDI cohort, though none reached statistical 
significance after adjustment for covariates. Other significant predictors of frailty-
associated conditions at 10 years included: antibiotic use within 10 years (OR 3.40, 99% 
CI 1.94-5.96), dementia at 10 years (OR 2.57, 99% CI 1.56-4.26), and renal disease at 10 




























Fluid & electrolyte 
imbalance 
















a10 year covariates included: bacteremia, pneumonia, skin infection, endocarditis, UTI, device infection, 
ART, shock, sepsis, perforated intestine, ileus, megacolon, acute renal failure, concomitant antibiotics, 
concomitant gastric acid suppressants, WBC, CRP, albumin, SCr, concomitant opioids, concomitant anti-
diarrheals, concomitant laxatives, ICU stay, hospital length of stay and the following assessed during 10 
years of follow-up: hypertension, dyslipidemia, irritable bowel disease, irritable bowel syndrome, obesity, 
GERD, transplant, schizophrenia, depression, bipolar, anxiety, PTSD, alcohol abuse, myocardial infarction, 
CHF, peripheral vascular disease, cerebral vascular disease, dementia, COPD, rheumatic disease, any liver 
disease, diabetes w/ and w/o complications, hemi/paraplegia, HIV/AIDS, any antibiotics (including high 
risk), in/outpatient visits, dialysis, LTCF stay. 
 
 
Finally, we assessed the correlation between the number of CDI episodes during 
follow-up at 10 years and the VA frailty index at 10 years. Number of CDI episodes was 
positively and significantly correlated with VA frailty index (p<0.0001), though little of 
the variability in the VA frailty index could be attributed to the number of CDI episodes 
(R2=0.0269) (Figure 5.7). We also assessed the relationship between the number of CDI 
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episodes and the development of any frailty-associated condition at 10 years and found a 
significant positive association (p<0.0001). Number of CDI episodes was also associated 
with individual frailty conditions at 10 years, including coagulopathy, involuntary weight 
loss, anemia, and falls (p<0.0001 for all).  
 






SUBGROUP ANALYSES: FEMALE-ONLY  
 Given that the VHA population is predominantly male, we conducted a subgroup 
analysis on female veterans only to assess the generalizability of our overall findings to 
females. Cohorts that were previously propensity score matched for mortality, aging, and 
frailty analyses were limited to female patients only. Table 5.11 presents the findings of 
the short and long-term outcomes.  
 Among females included in the study, CDI patients experienced significantly 
higher mortality compared to control patients and the risk after adjustment for covariates 
was highest early in the follow-up period (1 month OR 4.23, 99% CI 1.41-12.68) 
compared to 3-month and 12-month follow-ups. Interestingly, mortality was numerically 
lower among CDI patients at 10 years, though there were notably few patients available 
for the full 10-year follow-up resulting in imprecision in risk estimates (i.e., wide 
confidence intervals in multivariable models). Overall, mortality rates were much lower 
among this female subgroup compared to the overall population that was approximately 
94% male. For example, at 12 months, mortality among the CDI cohorts was lower 
among females compared to the overall cohort (11.6% vs. 27.7%) and lower among 
control females compared to overall controls (3.3% vs. 7.6%).  
 Analyses of aging-related conditions among females yielded similar results to 
overall findings: there was no significant difference in the development of aging-related 
conditions during short- or long-term follow-up. Similar to mortality, aging-related 
conditions were lower among females compared to males. For example, the development 
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of any aging-related condition at 12 months was lower among CDI females compared to 
the overall CDI cohort (8.6% vs. 15.6%).  
 Frailty analyses for females were somewhat different than the overall cohort. 
While frailty conditions were numerically lower, albeit by a smaller absolute percentage 
difference, the comparisons did not reach statistical significance for 1-month, 3-month, 
12-month, and 10 year follow-up periods. Similar to mortality, frailty-associated 
conditions were lower among females compared to males. For example, the development 
of any frailty-associated condition at 12 months was lower among CDI females compared 
to the overall CDI cohort (22.1% vs. 26.8%).  
 
Table 5.11. Prevalence of aging- and frailty-associated conditions and mortality at 
follow-up among female patients only 
 





   
1 month 42 (5.7%) 5 (0.7%) <0.0001 9.10 (3.58-23.13) 4.23 (1.41-12.68)c 
3 months 58 (7.8%) 13 (1.7%) <0.0001 4.89 (2.66-9.01) 2.50 (1.16-5.37)c 
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Aging-related conditions 
1 month n=548 n=573 
   
Any aging condition 18 (3.3%) 19 (3.3%) 0.9767 0.99 (0.51-1.91) 0.89 (0.36-2.17) 
Cardiovascular disease 4 (0.7%) 7 (1.2%) 0.4004 0.59 (0.17-2.04) 0.94 (0.16-5.69) 
Cancer 15 (2.7%) 10 (1.7%) 0.2597 1.58 (0.71-3.56) 1.23 (0.41-3.71) 
Neurodegenerative 
diseases 
0 (0.0%) 2 (0.3%) 0.1011 -- -- 
3 months n=540 n=569 
 
Any aging condition 22 (4.1%) 28 (4.9%) 0.4963 0.82 (0.46-1.45) 0.68 (0.29-1.58) 
Cardiovascular disease 6 (1.1%) 12 (2.1%) 0.1840 0.52 (0.19-1.40) 0.54 (0.10-2.81) 
Cancer 17 (3.1%) 14 (2.5%) 0.4873 1.29 (0.63-2.64) 1.25 (0.44-3.55) 
Neurodegenerative 
diseases 
1 (0.2%) 2 (0.4%) 0.5900 0.53 (0.05-5.82) -- 
12 months n=525 n=561 
 
Any aging condition 45 (8.6%) 69 
(12.3%) 
0.0443 0.67 (0.45-0.99) 0.40 (0.17-0.93)b 
Cardiovascular disease 19 (3.6%) 36 (6.4%) 0.0339 0.55 (0.31-0.97) 0.78 (0.27-2.38) 
Cancer 20 (3.8%) 23 (4.1%) 0.8062 0.93 (0.50-1.71) 0.78 (0.28-2.17) 
Neurodegenerative 
diseases 
11 (2.1%) 13 (2.3%) 0.8034 0.90 (0.40-2.03) 0.89 (0.15-5.18) 
10 years n=49 n=102 
 
Any aging condition 20(40.8%) 47(46.1%) 0.5416 0.81 (0.40-1.61) 2.75 (0.48-15.60) 
Cardiovascular disease 12(24.5%) 27(26.5%) 0.7940 0.90 (0.41-1.98) 0.60 (0.03-13.92) 
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Neurodegenerative diseases 4 (8.2%) 9 (8.8%) 0.6617 0.92 (0.27-3.14) -- 
Frailty-associated conditions 
1 month n=513 n=559 
 
Any frailty condition 39 (7.6%) 25(4.5%) 0.0304 1.76 (1.05-2.95) 0.98 (0.53-1.60) 
Coagulopathy 4 (0.8%) 3 (0.5%) 0.4530 1.46 (0.32-6.53) 1.40 (0.23-8.53) 
Weight loss 4 (0.8%) 2 (0.4%) 0.3039 2.19 (0.40-12.00) -- 
Fluid & electrolyte 
imbalance 
1 (0.2%) 0 (0.0%) 0.4785 -- -- 
Anemia 31 (6.0%) 16(2.9%) 0.0082 2.18 (1.18-4.04) 1.14 (0.54-2.39) 
Falls 2 (0.4%) 4 (0.7%) 0.8699 0.54 (0.10-2.98) -- 
Fractures 3 (0.6%) 3 (0.5%) 0.6156 1.09 (0.22-5.42) 1.05 (0.14-7.93) 
3 months n=504 n=556 
 
Any frailty condition 59(11.7%) 55(9.9%) 0.3413 1.22 (0.83-1.79) 0.83 (0.50-1.37) 
Coagulopathy 3 (0.6%) 6 (1.1%) 0.8846 0.55 (0.14-2.21) 1.02 (0.19-5.49) 
Weight loss 8 (1.6%) 4 (0.7%) 0.1486 2.23 (0.67-7.44) 0.98 (0.19-4.84) 
Fluid & electrolyte 
imbalance 
1 (0.2%) 0 (0.0%) 0.4755 -- -- 
Anemia 42 (8.3%) 36(6.5%) 0.1493 1.31 (0.83-2.09) 0.84 (0.46-1.53) 
Falls 5 (1.0%) 4 (0.7%) 0.6292 1.38 (0.37-5.18) 0.16 (0.02-1.63) 
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12 months n=488 n=551 
 
Any frailty condition 108(22.1%) 128(23.2%) 0.6728 0.93 (0.70-1.26) 1.28 (0.79-2.07) 
Coagulopathy 4 (0.8%) 8 (1.5%) 0.8943 0.56 (0.17-1.87) -- 
Weight loss 18 (3.7%) 13 (2.4%) 0.2090 1.58 (0.77-3.27) 1.14 (0.32-4.03) 
Fluid & electrolyte 
imbalance 
3 (0.6%) 2 (0.4%) 0.4432 1.69 (0.28-10.20) -- 
Anemia 65 (13.3%) 77 (14.0%) 0.7590 0.95 (0.66-1.35) 1.09 (0.63-1.89) 
Falls 12 (2.5%) 14 (2.5%) 0.9328 0.97 (0.44-2.11) 0.51 (0.07-3.49) 
Fractures 17 (3.5%) 23 (4.2%) 0.5627 0.83 (0.44-1.57) 3.75 (1.16-12.12)b 
10 years n=50 n=95 
 
Any frailty condition 32 (64.0%) 72 (75.8%) 0.1379 0.57 (0.27-1.19) -- 
Coagulopathy 3 (6.0%) 6 (6.3%) 0.6570 0.95 (0.23-3.96) -- 
Weight loss 6 (12.0%) 20 (21.1%) 0.9463 0.51 (0.19-1.37) -- 
Fluid & electrolyte 
imbalance 
0 (0.0%) 0 (0.0%) 1.0000 -- -- 
Anemia 15 (30.0%) 52 (54.7%) 0.0041 0.35 (0.17-0.73) -- 
Falls 6 (12.0%) 15 (15.8%) 0.8047 0.73 (0.26-2,01) -- 
Fractures 20 (40.0%) 34 (35.8%) 0.6189 1.19 (0.59-2.42) -- 
a1 month and 3 month covariates included: bacteremia, pneumonia, skin infection, endocarditis, UTI, device 
infection, ART, shock, sepsis, perforated intestine, ileus, megacolon, acute renal failure, concomitant 
antibiotics, concomitant gastric acid suppressants, WBC, CRP, albumin, SCr, concomitant opioids, 
concomitant anti-diarrheals, concomitant laxatives, ICU stay, hospital length of stay. 12 month and 10 year 
covariates included 1 and 3 month covariates plus the following assessed during 12 months or 10 years of 
follow-up: hypertension, dyslipidemia, irritable bowel disease, irritable bowel syndrome, obesity, GERD, 
transplant, schizophrenia, depression, bipolar, anxiety, PTSD, alcohol abuse, CHF, peripheral vascular 
disease, COPD, rheumatic disease, any liver disease, diabetes w/ and w/o complications, hemi/paraplegia, 




SUBGROUP ANALYSES: COMMUNITY-ONSET CDI ONLY 
CDI has traditionally been classified based on the setting on onset to assist 
healthcare providers with infection surveillance. CDI may be classified as community- or 
hospital-onset and also as healthcare facility-associated or not associated. Given that 
patients who develop CDI in the community may differ with respect to risk factors, 
presentation, and underlying conditions, and risk for poor outcomes we conducted a 
subgroup analysis on community-onset CDI (CO-CDI) veterans only to assess the 
generalizability of our overall findings to community-onset CDI only. The original CDI 
cohort was limited to community-onset CDI patients only (CO-HCFA-CDI and CA-
CDI), then new propensity score matched cohorts were created as described previously 
for mortality, aging, and frailty analyses. Table 5.12 presents the findings of the short and 
long-term outcomes.  
Among patients included in these subgroup analyses, CDI patients experienced 
significantly higher mortality at each follow-up compared to control patients and the risk 
after adjustment for covariates was highest early in the follow-up period (1 month OR 
2.99, 99% CI 2.49-3.59) compared to 3-month, 12-month, and 10-year follow-ups. 
Overall, mortality rates were lower among this CO-CDI subgroup compared to the 
overall population. For example, at 12 months, mortality among the CDI cohorts was 
lower among CO-CDI patients compared to the overall cohort (23.7% vs. 27.7%). 
Specifically, mortality was lowest for patients with CA-CDI (19.0%), followed by CO-
HCFA-CDI (27.6%), and HCFO-CDI (27.7%). This is likely due to lower rates of 
comorbidities and complications between these groups. The median baseline Charlson 
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comorbidity score was 1, 2, and 2, respectively in these groups. Common severity 
indicators were also least common among CA-CDI patients: sepsis 14.0%, 19.7%, 18.1% 
and acute renal failure 24.2%, 30.8%, 31.0%, respectively.  
Analyses of aging-related conditions among CO-CDI patients yielded similar 
results to overall findings: there was no significant difference in the development of 
aging-related conditions during short- or long-term follow-up. Similar to mortality, 
aging-related conditions were lower among CO-CDI patients compared to the overall 
cohort. For example, the development of any aging-related condition at 12 months was 
lower among CO-CDI patients compared to the overall CDI cohort (13.3% vs. 15.6%), 
though this difference was not as pronounced as we saw in the female subgroup 
analyses.  
Frailty analyses for CO-CDI patients demonstrated numerically somewhat higher 
rates of frailty-associated conditions at 1 month, 3 months, and 12 months, but lower 
rates at 10 years. None of these comparisons reached statistical significance though, 
unlike overall analyses that include HO-CDI patients. Frailty-associated conditions were 
only slightly lower among CO-CDI patients compared to the overall cohort. For example, 
the development of any frailty-associated condition at 12 months was 25.1% in the CO-





Table 5.12. Prevalence of mortality, aging-, and frailty-associated conditions at follow-









P-value OR (99% CI) Adjusted OR 
(99% CI)a 
Mortality 
1 month 1002(10.7%) 207 (2.2%) <0.0001 5.30 (4.55-6.18) 2.99 (2.49-3.59)c 
3 months 1250(13.4%) 305 (3.3%) <0.0001 4.18 (3.72-4.70) 2.44 (2.12-2.81)c 




10 years 1089(65.6%) 665 (47.8%) <0.0001 2.54 (2.21-2.94) 1.35 (1.01-1.80)b 
Aging-related conditions 
1 month n=5,280 n=5704 
 
Any aging condition 271 (5.1%) 265 (4.6%) 0.2370 1.11 (0.93-1.32) 0.80 (0.65-1.00) 
Cardiovascular 
disease 
101 (1.9%) 105 (1.8%) 0.7809 1.04 (0.79-1.37) 0.88 (0.62-1.24) 
Cancer 143 (2.7%) 145 (2.5%) 0.5860 1.07 (0.84-1.35) 0.69 (0.52-0.92)b 
Neurodegenerative 
diseases 
44 (0.8%) 26 (0.5%) 0.0127 1.84 (1.13-2.98) 1.48 (0.81-2.71) 
3 months n=5100 n=5645 
 
Any aging condition 411 (8.1%) 458 (8.1%) 0.9175 0.99 (0.86-1.14) 0.81 (0.68-0.96)b 
Cardiovascular 
disease 
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Cancer 218(4.3%) 220(3.9%) 0.3237 1.10 (0.91-1.33) 0.81 (0.64-1.03) 
Neurodegenerative 
diseases 
75 (1.5%) 55 (1.0%) 0.0188 1.52 (1.07-2.15) 1.68 (1.07-2.63)b 
12 months n=4714 n=5476 
 
Any aging condition 628(13.3%) 808(14.8%) 0.0379 0.89 (0.79-0.99) 1.02 (0.84-1.23) 
Cardiovascular 
disease 
308 (6.5%) 447 (8.2%) 0.0017 0.89 (0.68-0.91) 0.87 (0.55-1.36) 
Cancer 254 (5.4%) 295 (5.4%) 0.9981 1.00 (0.84-1.19) 1.02 (0.82-1.28) 
Neurodegenerative 
diseases 
136 (2.9%) 143 (2.6%) 0.3992 1.11 (0.87-1.41) 1.45 (1.01-2.08) 
10 years n=396 n=599 
 
Any aging condition 159(40.2%) 317(52.9%) <0.0001 0.60 (0.46-0.77) 2.12 (0.70-6.36) 
Cardiovascular 
disease 
91 (23.0%) 191(31.9%) 0.0021 0.64  (0.48-0.85) 1.07 (0.20-5.64) 
Cancer 81 (20.5%) 152(25.4%) 0.0711 0.76 (0.56-1.03) 1.07 (0.63-1.81) 
Neurodegenerative 
diseases 
52 (13.1%) 84 (14.0%) 0.6879 0.93 (0.64-1.34) 1.52 (0.68-3.41) 
Frailty-associated conditions 
1 month n=5163 n=5570 
 
Any frailty condition 398 (7.7%) 349 (6.3%) 0.0033 1.25 (1.08-1.45) 0.81 (0.68-0.97) 
Coagulopathy 22 (0.4%) 21 (0.4%) 0.6876 1.13 (0.62-2.06) 0.93 (0.47-1.84) 
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Fluid & electrolyte 
imbalance 
6 (0.1%) 3 (0.1%) 0.2179 2.16 (0.54-8.64) 1.96 (0.42-9.21) 
Anemia 288 (5.6%) 241 (4.3%) 0.0028 1.31 (1.09-1.56) 0.74 (0.59-0.92)b 
Falls 26 (0.5%) 26 (0.5%) 0.7839 1.08 (0.63-1.86) 0.94 (0.49-1.79) 
Fractures 26 (0.5%) 61 (1.1%) 0.0005 0.46 (0.29-0.72) 0.48 (0.28-0.82)b 
3 months n=4986 n=5499 
 
Any frailty condition 696(14.0%) 600(10.9%) <0.0001 1.32 (1.18-1.49) 0.91 (0.78-1.05) 
Coagulopathy 38 (0.8%) 32 (0.6%) 0.2581 1.31 (0.82-2.10) 1.02 (0.58-1.79) 
Weight loss 125 (2.5%) 60 (1.1%) <0.0001 2.33 (1.71-3.18) 1.48 (1.03-2.12)b 
Fluid & electrolyte 
imbalance 
8 (0.2%) 6 (0.1%) 0.3255 1.47 (0.51-4.24) 2.19 (0.58-8.31) 
Anemia 485 (9.7%) 411 (7.5%) <0.0001 1.33 (1.16-1.53) 0.85 (0.72-1.01) 
Falls 50 (1.0%) 47 (0.9%) 0.4292 1.18 (0.79-1.75) 1.04 (0.63-1.71) 
Fractures 62 (1.2%) 101 (1.8%) 0.0136 0.67 (0.49-0.93) 0.65 (0.45-0.95)b 
12 months n=4581 n=5330 
 




0.0657 1.09 (0.99-1.19) 1.18 (1.03-1.35)b 
Coagulopathy 69 (1.5%) 79 (1.5%) 0.9216 1.02 (0.73-1.41) 1.27 (0.83-1.93) 
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Fluid & electrolyte 
imbalance 
15 (0.3%) 18 (0.3%) 0.9294 0.97 (0.49-1.93) 1.94 (0.64-5.88) 
Anemia 771(16.8%) 772(14.5%) 0.0013 1.19 (1.07-1.33) 1.16 (0.99-1.36) 
Falls 108 (2.4%) 139 (2.6%) 0.4248 0.90 (0.69-1.16) 0.93 (0.66-1.32) 
Fractures 164 (3.6%) 238 (4.5%) 0.0254 0.79 (0.65-0.97) 0.95 (0.72-1.24) 
10 years n=391 n=647 
 
Any frailty condition 213(54.5%) 459(70.9%) <0.0001 0.49 (0.38-0.64) 1.21 (0.72-2.05) 
Coagulopathy 26 (6.7%) 50 (7.8%) 0.5156 0.85 (0.52-1.39) 1.67  (0.75-3.69) 
Weight loss 63 (16.1%) 117(18.1%) 0.4145 0.87 (0.62-1.22) 1.39 (0.78-2.49) 
Fluid & electrolyte 
imbalance 
5 (1.3%) 14 (2.2%) 0.9008 0.59 (0.21-1.64) -- 
Anemia 147(37.6%) 307(47.5%) 0.0019 0.68 (0.52-0.86) 0.97 (0.61-1.55) 
Falls 32 (8.2%) 101(15.6%) 0.0004 0.48 (0.32-0.73) 0.64 (0.31-1.32) 
Fractures 83 (21.2%) 176(27.2%) 0.0298 0.72 (0.54-0.97) 1.00 (0.61-1.64) 
a1 month and 3 month covariates included: bacteremia, pneumonia, skin infection, endocarditis, UTI, device 
infection, ART, shock, sepsis, perforated intestine, ileus, megacolon, acute renal failure, concomitant 
antibiotics, concomitant gastric acid suppressants, WBC, CRP, albumin, SCr, concomitant opioids, 
concomitant anti-diarrheals, concomitant laxatives, ICU stay, hospital length of stay. 12 month and 10 year 
covariates included 1 and 3 month covariates plus the following assessed during 12 months or 10 years of 
follow-up: hypertension, dyslipidemia, irritable bowel disease, irritable bowel syndrome, obesity, GERD, 
transplant, schizophrenia, depression, bipolar, anxiety, PTSD, alcohol abuse, CHF, peripheral vascular 
disease, COPD, rheumatic disease, any liver disease, diabetes w/ and w/o complications, hemi/paraplegia, 






Chapter 6:  Discussion 
CDI has been previously associated with poor health outcomes, including serious 
clinical signs/symptoms (e.g., frequent diarrhea leading to dehydration and electrolyte 
imbalances) and severe complications (e.g., sepsis, megacolon). Importantly, CDI is often 
preceded by disruption of the normal host gut microbiome, which can persist following 
the episode and lead to future recurrent CDI episodes and possibly risk for other 
microbiome-mediated conditions. Due to these effects, we evaluated the primary outcome 
of all-cause mortality in CDI patients compared to non-CDI controls in a national study 
of U.S. veterans. We then investigated risk for the development of secondary outcomes, 
including aging-related and frailty-associated conditions, in the same patient population. 
This is one of the first studies to evaluate long-term mortality rates in a CDI population 
and risk for non-infectious microbiome-mediated conditions. Overall, we found that CDI 
was associated with a significant increase in mortality in the short-term and long-term. 
CDI was also associated with short-term development of frailty-associated conditions, 
especially weight loss and anemia, but not chronic aging-related conditions.  
 ALL-CAUSE MORTALITY OUTCOMES 
 
All-cause mortality was common among CDI patients; more than one-quarter of 
CDI patients died within one year of the index episode compared to only 7.6% in the 
control group. Mortality risk was significantly higher among CDI patients at all three 
short-term follow-up periods (1-, 3-, and 12-months), with increased risk ranging from 
2.7 (at 12 months) to nearly 3.8 (at 1 month) times higher in CDI patients compared to 
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non-CDI controls. At the 10-year follow-up, mortality risk was nearly two times higher 
(OR 1.62) among CDI patients, with survival analyses showing a statistically significant 
difference in days to death among all of the follow-up time points (p<0.0001). 
Our findings of increased mortality risk in veterans with CDI is consistent with 
literature both within the VA patient population and the civilian population.55,58,59 
Mortality rates of CDI patients vary greatly between studies. Research in the VA 
population has shown mortality in CDI patients to range from 11% to 37% varying by 
severity,15,59 while non-VA data has cited higher rates (3%-43%),60-63 though there may 
be numerous reasons for these differences. First, more studies exist looking at mortality 
in the general CDI population as compared to veterans. Additionally, studies of this 
nature can be affected by the statistical methods used, the time frame in which mortality 
was assessed, and whether research was conducted during an epidemic or endemic 
periods of CDI in these populations. As well, European studies show a similar 
heterogeneity in all-cause mortality in CDI patients (ranging from 4-37%) when 
compared to US studies.64 Notably, in our study, we eliminated nearly 80% of the 
original unmatched CDI population to match with the non-CDI controls; thus, mortality 
rates reported in our study are likely lower than in the overall VA CDI population.  
 Here, and in a majority of previous CDI mortality outcome studies, the most 
pronounced mortality risk was early in the follow-up periods. Higher mortality earlier in 
the follow up period is not surprising, as the acute symptoms of infection can happen 
suddenly, quickly escalate, and may compound into serious complications. Specifically, 
short-term effects of CDI (and the resulting diarrhea) often include severe dehydration, 
 86 
gastrointestinal inflammation, loss of appetite, and poor nutritional intake and absorption. 
These symptoms can contribute to more serious complications in a short time frame, such 
as renal failure, sepsis, and others as previously described, increasing the risk for death 
earlier in the study period. 
Few studies have investigated long-term CDI outcomes, including mortality. 
Traditionally, CDI studies have defined “long-term” outcomes as those occurring at 1-
year post-CDI. There does not appear to be any research investigating long-term 
outcomes, including mortality, at the 10-year time frame or similar. Some retrospective 
studies have assessed CDI patients across a 10-year study period but did not have ten 
years of follow up data on patients as this study did. A recent study in the United 
Kingdom investigated mortality in CDI patients in the long-term, showing that CDI was 
associated with a 50% increased risk of death (HR 1.51 (99% CI: 1.05-2.19, p=0.03) at 
between five to eight years after adjusting for age, sex, the Charlson comorbidity index, 
malignancies, and nasogastric tube insertion during admission.65 
 Subgroups analyses were performed for two sample populations in this study: 
females and community-onset CDI (CO-CDI). Our results show female CDI mortality 
rates are lower than males, though prior literature does not show a consensus in regard to 
a relationship between sex and mortality outcomes with CDI.66,67 Female sex has 
previously been associated with higher CDI incidence;66-68 this is likely due to exposure 
to colonized infants, especially through breastfeeding, higher antibiotic prescribing rates, 
and that females are more likely to seek out medical care.68 Despite higher rates of 
infection, females in this study had less than half the mortality rate of males at each short-
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term follow-up period and lower mortality at 10 years (57% vs. 69%). In the short-term, 
these differences could be due to females being more likely to seek medical care earlier 
in the infection compared to males and to differences in certain mortality predictors 
compared to males. For example, certain comorbidities (e.g., metastatic cancer, 
moderate/severe liver disease) and complications (shock, acute renal failure) were less 
common among females compared to males. The long-term trends follow general 
longevity sex disparities in the U.S. On average, females live 6-8 years longer than males 
likely due to biological, social, and behavioral differences.69 
Community-onset CDI (CO-CDI) was also investigated as subgroup analyses. 
Similar to the female subgroup, mortality rates were lower in community-onset cases 
compared to hospital-onset cases. This was driven primarily by CA-CDI patients who 
had significantly lower mortality rates at 12 months compared to CO-HCFA-CDI and 
HCFO-CDI. The lower mortality rates among CA-CDI are likely related to the lower 
prevalence of underlying conditions and less severe infection. Specifically, CA-CDI 
patients had lower baseline Charlson comorbidity scores and fewer CDI complications. 
 
AGING-RELATED CONDITIONS OUTCOMES 
 
Any aging-related condition and individual aging-related conditions as defined 
previously were investigated as secondary outcomes of CDI compared to a non-CDI 
cohort. Bivariable analyses showed no statistically significant differences in the 
development of aging-related conditions in CDI patients compared to non-CDI controls. 
Although aging-related conditions were numerically higher in the CDI cohort in the 
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short-term, the differences were not statistically significant using a p-value cutoff of 
<0.0001. Regression analysis showed CDI as an independent predictor of cancer 
diagnosis at 1-month follow up, though this prediction trend was not true at 3- and 12- 
month follow up. We suspect this association may be due to detection of a malignant 
condition as a product of infection with C. difficile, and not necessarily development of 
the malignancy due to the infection itself. 
Previous literature has focused on the risk of CDI in patient populations already 
diagnosed with cardiovascular diseases, cancers, and neurodegenerative diseases. Studies 
have attributed increased CDI risk after cardiac procedures,70,71 immunosuppression from 
cancer and accompanying drug therapies,72 and prolonged hospitalization from 
multimorbidity.73 It does not appear that any prior research has investigated the opposite 
relationship: an increased risk of developing aging-related conditions post-CDI. Though 
most of this study’s findings for aging-relating conditions were not significant, we 
believe there is cause for further investigation into this area, especially in terms of 
prospective long-term follow up to determine a stronger potential relationship between 
CDI and these conditions.  
In regard to neurodegenerative conditions specifically, a 2012 study evaluated the 
host inflammatory response to toxigenic C. difficile infection in the rat model, showing 
that this infection led to increased neuroinflammation (among other types of 
inflammation).74 The secretion of neuropeptides as a strong neuroinflammatory response 
to CDI is important to the discussion of aging-related conditions, as neuroinflammation is 
a common factor in dementia and other neurodegenerative disorders.75 Though this study 
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did not evaluate the long-term effects of neuroinflammation, these data open up the 
possibility for an association between neurodegenerative disease development post-CDI. 
Further research should investigate measuring neuroinflammation in the animal, and 
possibly human, model pre- and post-CDI to prospectively identify neurodegenerative 
disease risk and development. 
We suspect that one of the reasons that CDI patients did not have significantly 
higher rates of aging-related conditions in the short- or long-term was because of the 
mortality disparity between these cohorts. Significantly more CDI patients died compared 
to controls and these patients were excluded from their respective follow-up analyses 
(e.g., patients who died within 1 month were excluded from aging-related condition 
analyses at 1 month). These data suggest that if patients are fit enough to survive the CDI 
encounter in the short-term, they are not likely to develop other chronic conditions in the 
long-term compared to matched controls.  
Analyses of the female subgroup showed lower rates of aging-related conditions 
compared to males. In short, women have lower rates of cardiovascular disease than men, 
though this varies based on the specific type of cardiovascular disease. A number of 
factors can impact this difference, including women taking more initiative with their 
general health and seeking preventive care (overall CVD), but taking longer to receive 
medical care for some events compared to men (e.g., acute coronary syndrome) as well as 
sex differences in the pharmacokinetics of cardiac drugs therapies (oral bioavailability, 
clearance, body fat distribution, plasma protein binding, and metabolism).76 Likewise, 
there are sex differences seen in cancer susceptibility, which is one of the most consistent 
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findings in epidemiological studies of cancer to date.77 The lifetime probability for 
developing cancer (including sex-specific cancers such as prostate and breast) is 
approximately 44.85% for males and 38.08% for females, despite males having a shorter 
life expectancy, with the same analysis showing that cancer mortality rates were also 
higher in males (223.0 vs. 153.2; ratio=1.46).77 Considering these data, it  is not 
surprising that after matching on aging-related conditions and analyzing females as a 
subgroup, rates were higher in males.  
Additionally, sex differences are well documented in neuropsychiatric and 
neurodegenerative disorders, as females have lower rates of some neurological conditions 
(e.g., Parkinson’s disease, 1:3.5 and amyotrophic lateral sclerosis, 1:1.6) but not others 
(e.g., Alzheimer’s 3:1, and multiple sclerosis, 2-3:1), which are attributed in large part to 
direct and indirect immunomodulatory actions of many sex steroid hormones.78 The rates 
of lower neurodegenerative disorders in this study is not surprising, despite the 3:1 ratio 
of Alzheimer’s in females compared to males. 
 
 
FRAILTY-ASSOCIATED CONDITIONS OUTCOMES 
 
Frailty and its associated conditions were also investigated as secondary outcomes 
of this study. Rates of frailty-associated conditions were numerically higher in the CDI 
cohort for all follow-up periods but was only statistically significant at 1-year follow up. 
This is not surprising as CDI and control patients were matched on the VA frailty index 
at baseline and patients with certain pre-existing frailty conditions were excluded at 
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baseline. Frailty is considered a chronic condition that may take several months to years 
to develop after a medical event.79 Similar to the aging condition analyses, we excluded 
patients who died at each follow-up period; thus, it is plausible that less frail patients 
ultimately survived resulting in diminished effect sizes for comparisons between the CDI 
and control groups over the follow-up periods.  
As previously mentioned, most prior studies have evaluated short-term CDI 
outcomes, with few studies evaluating long-term outcomes. This creates a limitation on 
studying the effects of CDI on frailty and frailty-associated conditions over time. Frailty-
associated conditions are commonly described in the CDI literature due to the acute 
nature of many of the symptoms and their sequelae which mimic frailty-associated 
conditions. For example, fluid and electrolyte imbalances are often seen quickly due to 
severe infectious diarrhea in a C. difficile positive patient resulting in dehydration. 
Therefore, correction of fluid and electrolyte imbalances are a common part of CDI 
management,80 as well as monitoring weight loss while receiving care. Additionally, CDI 
patients often experience loss of appetite, nausea/vomiting, and abdominal 
bloating/tenderness following a CDI episode, particularly with repeat episodes; thus, poor 
nutrition may result in weight and muscle loss. A combination of these symptoms is what 
increases the risk of more severe frailty-associated diagnoses, such as coagulopathy, 
which was statistically significant at 1-year follow up (p<0.0001). This may also explain 
why the primary drivers of the differences in frailty between groups in this study were 
involuntary weight loss and anemia. 
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Considering the severity differences seen in community-onset CDI compared to 
hospital-onset CDI, it is not surprising that our CO-CDI only cohort experienced lower 
frailty rates. Mild or moderate infections that can be treated without hospitalization, or 
advanced treatments such as surgery, are associated with better health outcomes overall 
and therefore have better expected recovery.81 Though hypervirulent strains (e.g., 
ribotype 027 or NAP1/B1/027) tend to cause more severe disease, we are unable to 
conclude the potential of these strains to cause increased risk of aging-related or frailty-
associated condition development post-CDI due to lack of strain data in this study and the 
lack of research regarding long-term microbiota implications between strains.  
 Correlation analyses were performed to assess the potential relationship over 
time between the number of CDI episodes and VA frailty index. This was assessed at 
both the 12-month follow-up and 10-year follow-up for appropriate patients (i.e., only 
those with 10 years of data were included in the 10-year correlation). Number of CDI 
episodes was positively and significantly correlated with VA frailty index at 12 months 
(p<0.0001) and 10-years (p<0.0001), though there was little variability in both analyses 
in which VA FI could be attributed directly to number of CDI episodes. Furthermore, 
there was a positive association between the number of CDI episodes and the 
development of any frailty associated condition at 1-year (p<0.0001) and 10 years 
(p<0.0001). This “dose-response” relationship strengthens our hypothesis that CDI is 
associated with the development of frailty conditions by demonstrating that the more CDI 
episodes a patient has, the higher their risk for frailty.  
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Frailty and decreased functional status have been previously reported as 
independent predictors of CDI,82 but also as predictors of recurrence within one year, 
morbidity, and mortality.83-85 Considering the impact that CDI has on the host’s frailty-
associated variables as previously discussed, it is important to consider how frailty post-
CDI will make the host vulnerable to multimorbidity, including an increased frailty 
index, and therefore, mortality. Using modified frailty indices, frailty has shown to be a 
predictor of mortality in those who developed more serious outcomes, such as 
colectomy.85 In summary, frailty can continue to affect CDI patients, even after recovery, 
as shown by their increased risk of recurrent infection. Frailty and its associated 





There are several strengths of our study design. First, combined CDI patients and 
controls produced a sample size of 112,806 patients, which allowed for powerful 
statistical comparisons between groups. The VHA is the largest integrated healthcare 
system in the U.S., which gave us full medical record access for all outpatient and 
inpatient VHA encounters for each patient over the study period, as long as the patient 
remained active in the VHA system. In addition, this study utilized a combination of 
ICD-9-CM/ICD-10-CM codes, positive stool tests for CDI, and documentation of CDI 
therapy to improve accuracy of CDI classification and minimize misclassification bias. 
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Prior studies have shown that there is good correlation between C. difficile toxin assay 
results and ICD-9-CM codes (the sensitivity and specificity of ICD-9-CM codes are 
estimated to be 71 to 78% and >99%, respectively in comparison to microbiologic data),48-
50 further reducing the risk of misclassification bias. Finally, the retrospective cohort 
design provided us with the ability to study aging- and frailty-related outcomes 
simultaneously as opposed to focusing on a single study outcome over a longer period of 
time than would be possible with a prospective design.  
LIMITATIONS 
  
As this is a retrospective study, there are inherent limitations. The data may be 
subject to misclassification bias, as mentioned previously, and confounding due to the use 
of administrative coding from electronic health records for data collection. Specifically, 
ICD-9-CM and ICD-10 codes were used during the respective study years in which they 
were integrated into the VHA; however, changes in coding for diagnoses over time might 
result in the potential for misclassification of some diagnoses. We attempted to minimize 
these limitations with the use of robust methods to confirm CDI classification, as 
mentioned in the strengths section, as well as control for confounding using propensity 
score-matched cohorts. The use of the veteran-only data provided us with predominantly 
elderly and male patients. The findings may therefore not be generalizable to non-VHA 
care settings; however, a large sample size of elderly patients will hold some 
generalizability to the average CDI patient population. In addition, the large sample size 
allowed us to conduct subgroup analyses on underrepresented groups (e.g., females), 
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though some subgroup analyses were underpowered for bivariable and multivariable 
analyses. It is possible that veterans sought care outside of the VHA system and certain 
outpatient or inpatient visits will be missed. Next, in the study time period, few VHA 
facilities were reporting C. difficile strain type (e.g., ribotype 027); thus, we were unable 
to evaluate the impact of specific C. difficile strains and health outcomes. Despite this, we 
were able to capture other CDI characteristics (community- vs. hospital-onset and 
severity), strengthening the potential association between CDI characteristics and aging- 
and frailty-related outcomes. Next, it may be difficult to infer a causal relationship 
between CDI and health outcomes, particularly those that develop later in the follow-up 
period (e.g., 10 years) because many other factors could have occurred during follow-up 
to predispose the patient to the outcome. As a result, we carefully considered the rate of 
outcomes over the course of 10 years, as well as controlled for new comorbidities and 
other important factors in our propensity score matched cohorts at each follow-up period. 
Finally, although the size and scope of our cohort is a major strength, the sample size 
could result in over-powered statistical comparisons, whereby even small differences 
between groups (i.e., small effect size) result in statistically significant differences 
between groups. To address this, we included a team of clinician-scientists who were able 
to provide expert opinions on the clinical significance of associations identified. 
CONCLUSIONS & FUTURE DIRECTIONS  
 
Despite advances in infection prevention and antimicrobial stewardship, CDI 
continues to threaten public health, including that of U.S. veterans. In this large-scale 
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retrospective study, we found that CDI was an independent predictor of mortality in the 
short- and long-term; this association was significant and believed to be at least partially 
responsible for the lack of significant associations between CDI and aging-related and 
frailty-associated outcomes. Despite numerically higher rates, CDI was not a statistically 
significant predictor of aging-related conditions; however, CDI was associated with 
frailty at 12 months and there was an association between number of CDI episodes and 
frailty index at 12 months and 10 years.  
Future directions of this research field should include two study paths: 1) 
prospectively measuring gut microbiome composition and recovery post-CDI while 
assessing the development of aging-related and frailty-associated outcomes to have 
stronger evidence of biological plausibility in regard to CDI increasing the risk of 
development of these conditions, and 2) evaluating interventions that can help mitigate 
mortality and the development of chronic conditions post-CDI. 
Overall, CDI prevention, effective treatment therapies, and recurrence avoidance 
should become and remain national level priorities in the Veterans Health Care System. 
With a high number of multimorbid patients, the VHA would benefit from preventing 
and adequately treating CDI as soon as possible, especially in high-risk patients. 
Additionally, the VHA should remain vigilant to current epidemic trends in CDI, as well 
as embrace new therapies as identified by continuously updated SHEA/IDSA C. difficile 




Chapter 7:  Relevance to Translational Science 
This research fulfilled the public health realm of the translational science 
spectrum, or the T4 phase as described in the accompanying figure below. In this stage of 
translational science research, we specifically pursued health outcomes research at the 
population level to determine the effects of CDI on aging and frailty development with 
the goal of generating new prevention, diagnosis, and treatment efforts. We intend to 
further pursue research at the T3 stage, which will include using the findings of this study 
to justify a prospective human study involving more in-depth gut microbiome research 
(clinical implementation, or T3 stage study), helping to guide basic scientists to 
determine more exact mechanisms of action regarding both CDI and the overall gut 
microbiome impact on healthy aging, jumpstarting research at the basic science and 
preclinical sciences research level (T0 and T1 stages). 
While translational science is often explained as a linear process, working only in 
the direction of bench-to-bedside, this study importantly showed that clinical 
observations at the patient management level can be critical in identifying new areas of 
research with regard to the gut microbiome’s complicated relationship with host disease, 
and ultimately, host aging processes. The results of this study will help build the 




Figure 7.1. Translational science approach of the current study, and its anticipated 







Appendix 1. ICD-9-CM and ICD-10-CM codes for comorbidities 
 
Comorbidity ICD-9-CM Code(s) ICD-10-CM Code(s) 
Myocardial infarction 410.x, 412.x I21.x, I22.x, I25.2 
Congestive heart failure 398.91, 402.01, 402.11, 
402.91, 404.01, 404.03, 
404.11, 404.13, 404.91, 
404.93, 425.4 - 425.9, 428.x 
I09.9, I11.0, I13.0, I13.2, I25.5, 




093.0, 437.3, 440.x, 441.x, 
443.1 - 443.9, 447.1, 557.1, 
557.9, V43.4 
I09.9, I11.0, I13.0, I13.2, I25.5, 
I42.0, I42.5 - I42.9, I43.x, I50.x, 
P29.0 
Cerebrovascular disease 362.34, 430.x - 438.x G45.x, G46.x, H34.0, I60.x - 
I69.x 




416.8, 416.9, 490.x - 505.x, 
506.4, 508.1, 508.8 
I27.8, I27.9, J40.x - J47.x, J60.x 
- J67.x, J68.4, J70.1, J70.3 
Rheumatic disease 446.5, 710.0 - 710.4, 714.0 - 
714.2, 714.8, 725.x 
M05.x, M06.x, M31.5, M32.x - 
M34.x, M35.1, M35.3, M36.0 
Peptic ulcer disease 531.x - 534.x K25.x - K28.x 
Mild liver disease 070.22, 070.23, 070.32, 
070.33, 070.44, 070.54, 070.6, 
070.9, 570.x, 571.x, 573.3, 
573.4, 573.8, 573.9, V42.7 
B18.x, K70.0 - K70.3, K70.9, 
K71.3 - K71.5, K71.7, K73.x, 
K74.x, K76.0, K76.2 - K76.4, 
K76.8, K76.9, Z94.4 
Diabetes without 
chronic complications 
250.0 - 250.3, 250.8, 250.9 E10.0, E10.1, E10.6, E10.8, 
E10.9, E11.0, E11.1, E11.6, 
E11.8, E11.9, E12.0, E12.1, 
E12.6, E12.8, E12.9, E13.0, 
E13.1, E13.6, E13.8, E13.9, 
E14.0, E14.1, E14.6, E14.8, 
E14.9 
Diabetes with chronic 
complications 
250.4 - 250.7 E10.2 - E10.5, E10.7, E11.2 - 
E11.5, E11.7, E12.2 - E12.5, 
E12.7, E13.2 - E13.5, E13.7, 
E14.2 - E14.5, E14.7 
Hemiplegia or 
paraplegia 
334.1, 342.x, 343.x, 344.0 - 
344.6, 344.9 
G04.1, G11.4, G80.1, G80.2, 
G81.x, G82.x, G83.0 - G83.4, 
G83.9 
Renal disease 403.01, 403.11, 403.91, 
404.02, 404.03, 404.12, 
404.13, 404.92, 404.93, 582.x, 
583.0 - 583.7, 585.x, 586.x, 
588.0, V42.0, V45.1, V56.x 
I12.0, I13.1, N03.2 - N03.7, 
N05.2 - N05.7, N18.x, N19.x, 
N25.0, Z49.0 - Z49.2, Z94.0, 
Z99.2 
 100 
Malignancy 140.x - 172.x, 174.x - 195.8, 
200.x - 208.x, 238.6 
C00.x - C26.x, C30.x - C34.x, 
C37.x - C41.x, C43.x, C45.x - 
C58.x, C60.x - C76.x, C81.x - 
C85.x, C88.x, C90.x - C97.x 
Moderate or severe liver 
disease 
456.0 - 456.2, 572.2- 572.8 I85.0, I85.9, I86.4, I98.2, K70.4, 
K71.1, K72.1, K72.9, K76.5, 
K76.6, K76.7 
Metastatic solid tumor 196.x - 199.x C77.x - C80.x 
AIDS/HIV 042.x - 044.x B20.x - B22.x, B24.x 
Hypertension 401-405 I10.x, I11.x, I12.x, I13.x, I15.x 
Dyslipidemia 272 E78.0-E78.5 
Obesity 278 E66.0x, E66.1, E66.2, E66.8, 
E66.9 
GERD 530.11, 530.81 K21.0, K21.9 
Transplant V42, E878.0 Z94.xx 
Inflammatory bowel 
disease 




Schizophrenia 295.x, 293.81 F06.2, F20.x, F21 
Depression 300.4, 301.1, 309.0 - 309.1, 
311, 298.0 
F31.4, F43.21, F32.9, F32.3 - 
F33.3 
Bipolar disorder 296.0 - 296.6 F30.x, F31.x 
Anxiety disorder 300.0, 300.2, 300.4, 309.2, 
313.0 




309.81 F43.10, F43.12 
Alcohol abuse 291.x, 303, 305 F10 
Bacteremia 790.7 R78.81 
Pneumonia 480.0-483.99, 485–487 J11.xx, J12.xx, J13.x-J16.x, 
J18.x 
Skin infection 680-686 L01-05.XX, L08.XX, K12.2 
Endocarditis 421.0, 421.1, 421.9, 424.9 I33.0X, I38, I39 
Urinary tract infection 590-599 N10, N11.X, N30.XX, N39.0 
Device-related infection 996.31, 996.62, 996.64, 999.31 T82.6, T82.7, T83.51, T83.6, 








562.00, 562.10, 562.11, 
562.01, 562.13, 562.03, 542, 
540-543, 540, 541, 567, 540.9 
K35.XX, K36, K37, K57.XX, 
K65.X, K67, K68.1X 
Shock 639.5, 785.52, 785.59 R57.0, R57.1, R57.8, R57.9, 
R65.21 




Perforated intestine 569.83 K63.1 
Ileus 560.1 K56.0, K56.4, K56.6X, K56.7 
Megacolon 558.2, 564.7 K52.1, K59.31, K59.30 
Acute renal failure 584, 586 N17.X 
 
Appendix 2. CDI Retrospective Study Data Dictionary 
  
 Variable  Definition  Data Type/Menu 
 DEMOGRAPHICS 
 Age  Date of first CDI encounter minus the date of birth (in years)  Continuous 
 Sex  Most common report of sex over the study period  Dichotomous (M,F) 
 Race  Most common report of race over the study period  Categorical (W,B,O) 
 Hispanic ethnicity  Most common report of Hispanic ethnicity over the study 
period 
 Dichotomous (1,0) 
 VHA priority group  Identified during first CDI encounter  Categorical (1-8) 
 VISN  Veterans Integrated Service Network during first encounter  Categorical 
 Prior hospitalization  Hospitalization within the 90-day period prior to encounter  Dichotomous (1,0) 
 EXPOSURES IN PAST YEAR 
 Inpatient visits  Total # of inpatient stays in last year  Continuous 
 Outpatient visits  Total # of outpatient visits in last year  Continuous 
 Chronic dialysis  ICD-10 codes Z99.2 or N18.6 in last year  Dichotomous (1,0) 
 Long-term care residence  Residence in a long-term care facility (nursing home, skilled 
nursing facility,  
 domiciliary) in the past year 
 Dichotomous (1,0) 
 MEDICATIONS IN PAST 90 DAYS 
 Antibiotics  Any antibiotic prescribed 2+ days in 90 days preceding 
encounter (Table 1) 
 Dichotomous (1,0) 
 Gastric acid suppressants  Any GAS prescribed 2+ days in 90 days preceding encounter 
(Table 2) 
 Dichotomous (1,0) 
 Laxatives  Any laxative prescribed 2+ days in 90 days preceding 
encounter (Table 3) 
 Dichotomous (1,0) 
 Antidiarrheals  Any antidiarrheal prescribed 2+ days in 90 days preceding 
encounter (Table 4) 
 Dichotomous (1,0) 
 Opioid analgesics   Any opioid prescribed 2+ days in the 90 days preceding 
encounter (Table 5) 
 Dichotomous (1,0) 
 Cancer chemotherapy  Any chemo prescribed 2+ days in the 90 days preceding 
encounter (Table 6) 
 Dichotomous (1,0) 
 COMORBIDITIES IN PAST YEAR 
 CDI  ICD-9 (008.45) or ICD-10 (A04.X) in the year preceding CDI 
encounter 
 Dichotomous (1,0) 
 Charlson comorbidities  Comorbidity in the year preceding CDI encounter (Table 7)  Dichotomous (1,0) 
 Selim comorbidities  Comorbidity in the year preceding CDI encounter (Table 7)  Dichotomous (1,0) 
 Other comorbidities  Comorbidity in the year preceding CDI encounter (Table 7)  Dichotomous (1,0) 
 Aging-related conditions  Condition in the year preceding CDI encounter (Table 7)  Dichotomous (1,0) 
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 Frailty-associated diagnoses  Diagnosis in the year preceding CDI encounter (Table 7)  Dichotomous (1,0) 
 ENCOUNTER CHARACTERISTICS 
 Treatment setting  Setting where CDI therapy began (CDI) or encounter 
occurred (controls) 
 Dichotomous (In,Out) 
 Severity indicators  Any severity indicator during the encounter (Table 7)  Dichotomous (1,0) 
 ICU admission  ICU admission any time during hospitalization  Dichotomous (1,0) 
 ICU <48 hours  ICU admission within first 48 hours of hospitalization  Dichotomous (1,0) 
 ICU ≥48 hours  ICU admission after first 48 hours of hospitalization  Dichotomous (1,0) 
 WBC ≥15 x109 cells/µL  White blood cell count ≥15 anytime during encounter  Dichotomous (1,0) 
 CRP ≥160 mg/L  C-reactive protein ≥160 anytime during encounter  Dichotomous (1,0) 
 Albumin <2.5 g/dL  Albumin <2.5 anytime during encounter  Dichotomous (1,0) 
 SCr >1.5 mg/dL  Serum creatinine >1.5 anytime during encounter  Dichotomous (1,0) 
 CDI therapies  Each CDI therapy prescribed for 2+ days during encounter   Dichotomous (1,0) 
 Any CDI therapy  CDI therapy started anytime during encounter (Table 8)  Dichotomous (1,0) 
 CDI therapy ≤48 hours  CDI therapy started outpatient or on inpatient day 1 or 2 
(Table 8) 
 Dichotomous (1,0) 
 CDI therapy >48 hours  CDI therapy started on or after day 3 of hospitalization (Table 
8) 
 Dichotomous (1,0) 
 HCFO-CDI  CDI therapy started on or after day 3 of hospitalization (Table 
8) 
 Dichotomous (1,0) 
 CA-CDI  CDI therapy started outpatient or on inpatient day 1 or 2 
(Table 8) 
 Dichotomous (1,0) 
 CO-HCFA-CDI  CDI therapy started outpatient or on inpatient day 1 or 2 + 
prior hospitalization 
 Dichotomous (1,0) 
 Concomitant infection  Any infection documented during the encounter (Table 7)  Dichotomous (1,0) 
 OUTCOMES AT 30 DAYS FOLLOW-UP 
 Mortality  Death within 30 days of CDI treatment/encounter end date  Dichotomous (1,0) 
 Recurrence  CDI ICD code within 30 days of CDI treatment end date + 3 
day gap 
 Dichotomous (1,0) 
 Aging-related conditions  Any condition within 30 days of CDI treatment/encounter end 
date (Table 7) 
 Dichotomous (1,0) 
 Frailty-associated diagnoses  Any diagnosis within 30 days of CDI treatment/encounter end 
date (Table 7) 
 Dichotomous (1,0) 
 VA Frailty Index Score  Calculated as # of deficits divided by 31 (Table 8) within 30 
days of CDI  
 treatment/encounter end date 
 Continuous (0 - 1) 
 OUTCOMES AT 60 DAYS FOLLOW-UP 
 Mortality  Death within 60 days of CDI treatment/encounter end date  Dichotomous (1,0) 
 Recurrence  CDI ICD code within 60 days of CDI treatment end date + 3 
day gap 
 Dichotomous (1,0) 
 Aging-related conditions  Any condition within 60 days of CDI treatment/encounter end 
date (Table 7) 
 Dichotomous (1,0) 
 Frailty-associated diagnoses  Any diagnosis within 60 days of CDI treatment/encounter end 
date (Table 7) 
 Dichotomous (1,0) 
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 VA Frailty Index Score  Calculated as # of deficits divided by 31 (Table 8) within 60 
days of CDI   
 treatment/encounter end date 
 Continuous (0 - 1) 
 OUTCOMES AT 90 DAYS FOLLOW-UP 
 Mortality  Death within 90 days of CDI treatment/encounter end date  Dichotomous (1,0) 
 Recurrence  CDI ICD code within 90 days of CDI treatment end date + 3 
day gap 
 Dichotomous (1,0) 
 Aging-related conditions  Any condition within 90 days of CDI treatment/encounter end 
date (Table 7) 
 Dichotomous (1,0) 
 Frailty-associated diagnoses  Any diagnosis within 90 days of CDI treatment/encounter end 
date (Table 7) 
 Dichotomous (1,0) 
 VA Frailty Index Score   Calculated as # of deficits divided by 31 (Table 8) within 90 
days of CDI  
 treatment/encounter end date 
 Continuous (0 - 1) 
 EXPOSURES AT 1 YEAR FOLLOW-UP 
 Inpatient visits  Total # of inpatient stays within 1 year of encounter end date  Continuous 
 Outpatient visits  Total # of outpatient visits within 1 year of encounter end date  Continuous 
 Chronic dialysis  ICD-10 codes Z99.2 or N18.6 within 1 year of encounter end 
date 
 Dichotomous (1,0) 
 Long-term care residence  Residence in a long-term care facility (nursing home, skilled 
nursing facility,   
 domiciliary) within 1 year of encounter end date 
 Dichotomous (1,0) 
 Number of CDI episodes  Total # of CDI encounters (ICD-9 008.45 or ICD-10 A04) 
within 1 year of first  
 encounter end date 
 Continuous 
 COMORBIDITIES AT 1 YEAR FOLLOW-UP 
 Charlson comorbidities  Comorbidity within 1 year of encounter end date (Table 7)  Dichotomous (1,0) 
 Selim comorbidities  Comorbidity within 1 year of encounter end date (Table 7)  Dichotomous (1,0) 
 Other comorbidities  Comorbidity within 1 year of encounter end date (Table 7)  Dichotomous (1,0) 
 MEDICATIONS AT 1 YEAR FOLLOW-UP 
 Antibiotics  Any antibiotic within 1 year of CDI treatment/encounter end 
date (Table 1) 
 Dichotomous (1,0) 
 Gastric acid suppressants  Any GAS within 1 year of CDI treatment/encounter end date 
(Table 2) 
 Dichotomous (1,0) 
 Laxatives  Any laxative within 1 year of CDI treatment/encounter end 
date (Table 3) 
 Dichotomous (1,0) 
 Antidiarrheals  Any antidiarrheal within 1 year of CDI treatment/encounter 
end date (Table 4) 
 Dichotomous (1,0) 
 Opioid analgesics   Any opioid within 1 year of CDI treatment/encounter end date 
(Table 5) 
 Dichotomous (1,0) 
 Cancer chemotherapy  Any chemo within 1 year of CDI treatment/encounter end 
date (Table 6) 
 Dichotomous (1,0) 
 OUTCOMES AT 1 YEAR FOLLOW-UP 
 Mortality  Death within 1 year of CDI treatment/encounter end date  Dichotomous (1,0) 
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 Recurrence  CDI ICD code within 1 year of CDI treatment end date + 3 
day gap 
 Dichotomous (1,0) 
 Aging-related conditions  Any condition within 1 year of CDI treatment/encounter end 
date (Table 7) 
 Dichotomous (1,0) 
 Frailty-associated diagnoses  Any diagnosis within 1 year of CDI treatment/encounter end 
date (Table 7) 
 Dichotomous (1,0) 
 VA Frailty Index Score  Calculated as # of deficits divided by 31 (Table 8) within 1 
year of CDI  
 treatment/encounter end date 
 Continuous (0 - 1) 
 EXPOSURES AT 10 YEAR FOLLOW-UP 
 Inpatient visits  Total # of inpatient stays within 10 years of encounter end 
date 
 Continuous 
 Outpatient visits  Total # of outpatient visits within 10 years of encounter end 
date 
 Continuous 
 Chronic dialysis  ICD-10 codes Z99.2 or N18.6 within 10 years of encounter 
end date 
 Dichotomous (1,0) 
 Long-term care residence  Residence in a long-term care facility (nursing home, skilled 
nursing facility,   
 domiciliary) within 10 years of encounter end date 
 Dichotomous (1,0) 
 Number of CDI episodes  Total # of CDI encounters (ICD-9 008.45 or ICD-10 A04) 
within 10 years of first  
 encounter end date 
 Continuous 
 COMORBIDITIES AT 10 YEAR FOLLOW-UP 
 Charlson comorbidities  Comorbidity within 10 years of encounter end date (Table 7)  Dichotomous (1,0) 
 Selim comorbidities  Comorbidity within 10 years of encounter end date (Table 7)  Dichotomous (1,0) 
 Other comorbidities  Comorbidity within 10 years of encounter end date (Table 7)  Dichotomous (1,0) 
 MEDICATIONS AT 10 YEAR FOLLOW-UP 
 Antibiotics  Any antibiotic within 10 years of CDI treatment/encounter 
end date  (Table 1) 
 Dichotomous (1,0) 
 Gastric acid suppressants  Any GAS within 10 years of CDI treatment/encounter end 
date (Table 2) 
 Dichotomous (1,0) 
 Laxatives  Any laxative within 10 years of CDI treatment/encounter end 
date (Table 3) 
 Dichotomous (1,0) 
 Antidiarrheals  Any antidiarrheal within 10 years of CDI treatment/encounter 
end date (Table 4) 
 Dichotomous (1,0) 
 Opioid analgesics   Any opioid within 10 years of CDI treatment/encounter end 
date (Table 5) 
 Dichotomous (1,0) 
 Cancer chemotherapy  Any chemo within 10 years of CDI treatment/encounter end 
date (Table 6) 
 Dichotomous (1,0) 
 OUTCOMES AT 10 YEAR FOLLOW-UP 
 Mortality  Death within 10 years of CDI treatment/encounter end date  Dichotomous (1,0) 
 Recurrence  CDI ICD code within 10 years of CDI treatment end date + 3 
day gap 
 Dichotomous (1,0) 
 Aging-related conditions  Any condition within 10 years of CDI treatment/encounter 
end date (Table 7) 
 Dichotomous (1,0) 
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 Frailty-associated diagnoses  Any diagnosis within 10 years of CDI treatment/encounter 
end date (Table 7) 
 Dichotomous (1,0) 
 VA Frailty Index Score  Calculated as # of deficits divided by 31 (Table 8) within 10 
years of CDI  
 treatment/encounter end date 
 Continuous  
 Time to mortality  Date of death minus date of CDI treatment/encounter end date 
plus one (days) 




Appendix 3. Non-CDI antibiotics 
 
Generic Name Brand Name(s) 
Penicillin G Pfizerpen 





Nafcillin Nallpen, Unipen 
Oxacillin Bactocill 
Amoxicillin-clavulanate Augmentin 







Cefaclor Ceclor, Raniclor 
Cefprozil Cefzil 






























Trimethoprim-sulfamethoxazole Bactrim, Septra 










Doxycycline Doryx, Vibramycin, Oracea 








Appendix 4. Gastric acid suppressant medications 
 
Generic name Brand name(s) 
Omeprazole Prilosec, Zegerid 
Lansoprazole Prevacid 
Dexlansoprazole Kapidex, Dexilant 







Calcium carbonate Tums, Rolaids 
Magnesium hydroxide Rolaids, Milk of Magnesia 
Magnesium oxide Mag-Ox, MagGel, Uro-Mag, Mag-200 
Bismuth subsalicylate Pepto Bismol, Kaopectate 
 
Appendix 5. Laxatives 
 
Generic name Brand name 
Magnesium citrate Phillips' Milk of Magnesia 
Magnesium hydroxide Phillips' Milk of Magnesia 
Magnesium oxide Prepopik 
Magnesium sulfate Suprep 
Sodium phosphate Fleet Enema 
Senna Senokot 
Bisacodyl Dulcolax 
Castor oil   
Methylcellulose Citrucel 
Psyllium Metamucil 
Wheat dextrin Benefiber 
Mineral oil   
Docusate Peri-Colace, Colace, Surfak 
Glycerin   
Lactulose   
Polyethylene glycol 3350 (PEG) GlycoLax, MiraLax 








Appendix 6. Anti-diarrheals 
 
Generic Name Brand Name 
Atropine and diphenoxylate Lomotil 
Bismuth subsalicylate Bismatrol, Diotame, Geri-Pectate, Kao-Tin, Peptic Relief, Pepto-
Bismol, Pink Bismuth, Stomach Relief  
Loperamide Anti-Diarrheal, Diamode, Immodium A-D, Loperamide A-D 
 

















Appendix 8. Cancer chemotherapy 
 
Class Generic Name Brand Name(s) 
Alkylating agent Cyclophosphamide Cytoxan 
  Ifosfamide Ifex 
  Temozolomide Temodar 
  Dacarbazine DTIC 
  Melphalan Alkeran 
  Busulfan Myleran 
  Lomustine CeeNU 
  Carmustine BiCNU, Gliadel 
  Procarbazine Matulane 
  Chlorambucil Leukeran 
  Mechlorethamine Mustargen 
  Streptozosin Zanosar 
  Altretamine Hexalen 
  Thiotepa Thioplex 
  Bendamustine Treanda 
  Estramustine Emcyt 
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Anthracyclines Doxorubicin Adriamycin 
  Doxorubicin 
liposomal 
Doxil 
  Epirubicin Ellence 
  Idarubicin Idamycin 
  Daunorubicin Cerubidine 
  Daunorubicin 
liposomal 
DaunoXome 
  Mitoxantrone Novantrone 
  Valrubicin Valstar 
Platinum analogs Cisplatin Platinol 
  Carboplatin Paraplatin-AQ 
  Oxaliplatin Eloxatin 
Folate antimetabolites Methotrexate Trexall, Otrexup, Rasuvo, 
Rheumatrex 
  Pemetrexed Alimta 
  Pralatrexate Folotyn 
  Ralitrexed Tomudex 
Pyrimidine analogs Capecitabine Xeloda 
  Cytarabine Ara-C, Cytosar 
  Floxuridine FUDR 
  Fluorouracil, 5-FU Adrucil 
  Gemcitabine Gemzar 
Taxanes Paclitaxel Taxol 
  Paclitaxel protein 
bound 
Abraxane 
  Docetaxel Taxotere 
  Cabazitaxel Jevtana 
Vinka alkaloids Vincristine Vincasar, Oncovin 
  Vincristine liposomal Marqibo 
  Vinblastine Velban 
  Vindesine . 




  Irinotecan liposomal Onivyde 




  Teniposide Vumon 
Epothilone Ixabepilone Ixempra 
Miscellaneous agents Tretinoin All-trans retinoic acid, ATRA 
Vesanoid 
  Arsenic trioxide Trisenox 
 110 
  L-Asparaginase Elspar 
  Asparaginase Erwinaze 
  Pegaspargase Oncaspar 
  Bleomycin . 
  Mitomycin Mutamycin 
Antiandrogen Bicalutamide Casodex 
  Flutamide Eulexin 
  Nilutamide Nilandron 
  Degarelix Firmagon 
  Abiraterone acetate Zytiga 




  Leuprolide Lupron, Eligard, Viadur 
  Histrelin Vantas 
  Triptorelin Trelstar 
Aromatase inhibitor Anastrozole Arimidex 
  Letrozole Femara 
  Exemestane Aromasin 
Antiestrogens Tamoxifen Soltamox 
  Fulvestrant Faslodex 




  Alectinib Alecensa 
  Brigatinib Alunbrig 
  Sunitinib Sutent 
  Vandetanib Caprelsa 
  Cabozantinib Cabometyx, Cometriq 
  Pazopanib Votrient 
  Sorafenib Nexavar 
  Axitinib Inlyta 
  Imatinib Gleevec 
  Nilotinib Tasigna 
  Dasatinib Sprycel 
  Ponatinib Iclusig 
  Bosutinib Bosulif 
  Lenvatinib Lenvima 
  Midostaurin Rydapt 
  Osimertinib Tagrisso 
  Regorafenib Stivarga 
  Erlotinib Tarceva 
  Afatinib Gilotrif 
  Ceritinib Zykadia 
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  Crizotinib Xalkori 
  Vemurafenib Zelboraf 
  Dabrafenib Tafinlar 
  Gefitinib Iressa 
  Ibrutinib Imbruvica 
mTOR inhibitors Everolimus Afinitor 
  Temsirolimus Torisel 
MEK1 and MEK2 
inhibitor 
Trametinib Mekinist 
  Cobimetinib Cotellic 
Immunomodulators Lenalidomide Revlimid 
  Pomalidomide Pomalyst 
  Thalidomide Thalomid 
  Interferon Alfa-2b Intron A 
  Peginterferon Alfa-2b PegIntron 
Proteasome inhibitors Bortezomib Velcade 
  Carfilzomib Kyprolis 




Appendix 9. Comorbidities/diagnosis   
 
Comorbidity ICD-9-CM Code(s) ICD-10-CM Code(s) 
CHARLSON COMORBIDITIES 
Myocardial infarction 410.x, 412.x I21.x, I22.x, I25.2 
Congestive heart failure 398.91, 402.01, 402.11, 402.91, 
404.01, 404.03, 404.11, 404.13, 
404.91, 404.93, 425.4 - 425.9, 428.x 
I09.9, I11.0, I13.0, I13.2, I25.5, 
I42.0, I42.5 - I42.9, I43.x, I50.x, 
P29.0 
Peripheral vascular disease 093.0, 437.3, 440.x, 441.x, 443.1 - 
443.9, 447.1, 557.1, 557.9, V43.4 
I09.9, I11.0, I13.0, I13.2, I25.5, 
I42.0, I42.5 - I42.9, I43.x, I50.x, 
P29.0 
Cerebrovascular disease 362.34, 430.x - 438.x G45.x, G46.x, H34.0, I60.x - I69.x 
Dementia 290.x, 294.1, 331.2 F00.x - F03.x, F05.1, G30.x, G31.1 
Chronic pulmonary disease 416.8, 416.9, 490.x - 505.x, 506.4, 
508.1, 508.8 
I27.8, I27.9, J40.x - J47.x, J60.x - 
J67.x, J68.4, J70.1, J70.3 
Rheumatic disease 446.5, 710.0 - 710.4, 714.0 - 714.2, 
714.8, 725.x 
M05.x, M06.x, M31.5, M32.x - 
M34.x, M35.1, M35.3, M36.0 
Peptic ulcer disease 531.x - 534.x K25.x - K28.x 
Mild liver disease 070.22, 070.23, 070.32, 070.33, 
070.44, 070.54, 070.6, 070.9, 570.x, 
571.x, 573.3, 573.4, 573.8, 573.9, 
V42.7 
B18.x, K70.0 - K70.3, K70.9, 
K71.3 - K71.5, K71.7, K73.x, 
K74.x, K76.0, K76.2 - K76.4, 
K76.8, K76.9, Z94.4 
Diabetes without complications 250.0 - 250.3, 250.8, 250.9 E10.0, E10.1, E10.6, E10.8, E10.9, 
E11.0, E11.1, E11.6, E11.8, E11.9, 
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E12.0, E12.1, E12.6, E12.8, E12.9, 
E13.0, E13.1, E13.6, E13.8, E13.9, 
E14.0, E14.1, E14.6, E14.8, E14.9 
Diabetes with complications 250.4 - 250.7 E10.2 - E10.5, E10.7, E11.2 - 
E11.5, E11.7, E12.2 - E12.5, E12.7, 
E13.2 - E13.5, E13.7, E14.2 - 
E14.5, E14.7 
Hemiplegia or paraplegia 334.1, 342.x, 343.x, 344.0 - 344.6, 
344.9 
G04.1, G11.4, G80.1, G80.2, G81.x, 
G82.x, G83.0 - G83.4, G83.9 
Renal disease 403.01, 403.11, 403.91, 404.02, 
404.03, 404.12, 404.13, 404.92, 
404.93, 582.x, 583.0 - 583.7, 585.x, 
586.x, 588.0, V42.0, V45.1, V56.x 
I12.0, I13.1, N03.2 - N03.7, N05.2 - 
N05.7, N18.x, N19.x, N25.0, Z49.0 
- Z49.2, Z94.0, Z99.2 
Malignancy 140.x - 172.x, 174.x - 195.8, 200.x - 
208.x, 238.6 
C00.x - C26.x, C30.x - C34.x, 
C37.x - C41.x, C43.x, C45.x - 
C58.x, C60.x - C76.x, C81.x - 
C85.x, C88.x, C90.x - C97.x 
Moderate/severe liver disease 456.0 - 456.2, 572.2- 572.8 I85.0, I85.9, I86.4, I98.2, K70.4, 
K71.1, K72.1, K72.9, K76.5, K76.6, 
K76.7 
Metastatic solid tumor 196.x - 199.x C77.x - C80.x 
AIDS/HIV 042.x - 044.x B20.x - B22.x, B24.x 
OTHER COMORBIDITIES 
Hypertension 401-405 I10.x, I11.x, I12.x, I13.x, I15.x 
Dyslipidemia 272 E78.0-E78.5 
Obesity 278 E66.0x, E66.1, E66.2, E66.8, E66.9 
GERD 530.11, 530.81 K21.0, K21.9 
Transplant V42, E878.0 Z94.xx 
Inflammatory bowel disease 555.0-2, 555.9, 556.0-9 K50.XX, K51.XX, K52.3 
Irritable bowel syndrome 564.1 K58.9 
SELIM COMORBIDITIES 
Schizophrenia 295.x, 293.81 F06.2, F20.x, F21 
Depression 300.4, 301.1, 309.0 - 309.1, 311, 
298.0 
F31.4, F43.21, F32.9, F32.3 - F33.3 
Bipolar disorder 296.0 - 296.6 F30.x, F31.x 
Anxiety disorder 300.0, 300.2, 300.4, 309.2, 313.0 F06.4, F40.x, F41.x, F93.0 - F93.2 
Post-traumatic stress disorder 309.81 F43.10, F43.12 
Alcohol abuse 291.x, 303, 305 F10 
CONCOMITANT INFECTIONS 
Bacteremia 790.7 R78.81 
Pneumonia 480.0-483.99, 485–487 J11.xx, J12.xx, J13.x-J16.x, J18.x 
Skin infection 680-686 L01-05.XX, L08.XX, K12.2 
Endocarditis 421.0, 421.1, 421.9, 424.9 I33.0X, I38, I39 
Urinary tract infection 590-599 N10, N11.X, N30.XX, N39.0 
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Device-related infection 996.31, 996.62, 996.64, 999.31 T82.6, T82.7, T83.51, T83.6, 
T84.50, T84.60, T84.7, T85.71, 
T85.79 
Acute respiratory infection 460-466 J00, J01.XX, J02-6.X, J20.X, J21.X 
Intra-abdominal infections 562.00, 562.10, 562.11, 562.01, 
562.13, 562.03, 542, 540-543, 540, 
541, 567, 540.9 
K35.XX, K36, K37, K57.XX, 
K65.X, K67, K68.1X 
SEVERITY INDICATORS 
Shock 639.5, 785.52, 785.59 R57.0, R57.1, R57.8, R57.9, R65.21 
Sepsis 020.2, 038.0-038.9, 995.91, 995.92 R65.2X, A41.X 
Perforated intestine 569.83 K63.1 
Ileus 560.1 K56.0, K56.4, K56.6X, K56.7 
Megacolon 558.2, 564.7 K52.1, K59.31, K59.30 
Acute renal failure 584, 586 N17.X 
AGING-RELATED CONDITIONS 
Neurodegenerative diseases 290, 294, 331-2  G20, G30-1, F01-3 
Cardiovascular diseases 410, 412, 430-438 I21, I63.0-I63.9  
FRAILTY-ASSOCIATED DIAGNOSES 
Coagulopathy 286.0-286.9 D65-D69 
Involuntary weight loss 783.21 R63.4 
Fluid & electrolyte imbalance 276.9 E87 
Anemia 280.0-285.9 D60-D64 
Falls V15.88 Z91.81  




Appendix 10. CDI therapies 
Generic Name Brand Name(s) 
Metronidazole (oral or IV) Flagyl 




Saccharomyces boulardii Florastor 
Lactobacillus Acidophilus 
Bifidobacterium Align 
Intravenous immune globulin Flebogamma, Carimune, Gammagard, Gamunex, Iveegam, Octagam, Polygam 




Appendix 11. VA Frailty Index Score (VA-FI) variable list and assigned patient values. 
A value of 1 is assigned if the variable is present in the patient’s chart at the point of preview. A 
value of 0 is assigned if the variable is not present. (Unless otherwise stated). The final coding 
equation will include the number of variables present divided by the total number of variables in 
the index, for example: 
If a patient has 10 of the 31 variables (deficits) present, they would be coded as: 10/31 = 0.33, 
qualifying them as moderately frail based on the validated groups we will be using (Table 10 
below). In analyses comparing frail vs. non-frail, frailty should be considered any score of 0.21 or 
greater.  
VA Frailty Index 
Variable 
ICD-9-CM Code(s) ICD-10-CM Code(s) 
Anemia 280.0-285.9 D50-D64.9 
Atrial Fibrillation 427.3, 427.31 I48.x 
Cancer (any except basal 
cell skin cancer) 
140 - 200 
EXCLUDING: 173.01, 173.11, 
173.21, 173.31, 173,41, 173.51, 
173.61, 173.71, 173,81, 173.91 




C44.319, C44.41, C44.510, 
C44.511, C44.519, 











Coronary Artery Disease: 
MI, CABG, or PCI 
410.x, 412.x, 414.04, 429.2, 
429.5 
429.7, V45.82 
I21.x, I22.x, I25.10, I25.2, 
I51.1, I25.709, I25.810, 
Z98.61 
Diabetes 250.00, 250.02, 250.10, 250.12, 
250.20, 250.22 
250.30, 250.32, 250.40, 250.42, 
250.50, 250.52 
250.60, 250.62, 250.70, 250.72, 
250.80, 250.82 
250.90, 250.92 
E11.9, E11.65, E11.69, 
E13.10, E11.00, E11.01, 
E11.641, E11.29, E11.21, 
E11.311, E11.319, E11.36, 
E11.39, E11.40, E11.51, 
E11.51, E11.618, E11.620, 
E11.621, E11.622, 
E11.628, E11.630, 
E11.638, E11.649, E11.8 
Heart Failure (diastolic or 
systolic) 
428.x, 402.01, 402.11, 402.91, 
404.01, 404.03, 404.11, 404.13, 
404.91, 404.93 
I50.x, I11.0, I13.0, I13.2 
Hypertension 401 - 405 I10.x, I11.x, I12.x, I13.x, 
I15.x 
Kidney Disease 
(Chronic Kidney Disease 
code = 0.5, 
Chronic Kidney Disease 
(receives value of 0.5): 250.4, 
Chronic Kidney Disease 
(receives value of 0.5): 
I12.0, I12.9, I13.0, I13.1, 
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Dialysis code =1) 403.00, 403.10, 403.90, 404.00, 
404.01 
404.10 - 404.11, 404.90, 
404.91, 585 - 588, 
582.x 
Dialysis: 403.01, 403.11, 
403.91, 
404.02 - 404.03, 404.12 - 
404.13, 404.92 - 404.93, V42, 
V56, V45.1, E879.1 
N03.2 - N03.7, N05.2 - 
N05.7, N18.x, N19.x, 
N25.x, Z94.0, 
 
Dialysis: I13.11, I13.2, 
Z99.2, Z49.0 - Z49.2 
 
Liver Disease or 
Cirrhosis 
570 - 571, 572.2, 572.3, 572.8, 
573 
006.3, 070.x, V42.7 
B18.x, K70.x - K77.x, 
Z94.4 
A06.4, B18 - B19, Z94.4 
Lung disease: COPD  
or Asthma 
490 - 496, 510 J41.x, J44.x, J45.x 
Thyroid Disease 240, 241, 242, 244 - 245, 246.0, 
246.3 - 246.9 





733.0, 733.13 M80, M81, M82, M84 
Incontinence 625.6, 787.6, 788.3, 788.91 N39.3, N39.4, R39.8 
Arthritis (rheumatoid 
arthritis or osteoarthritis) 
274, 446.5, 710.9, 714.0 - 
714.2, 714.4, 714.89, 714.9, 
715, 716.1 - 716.3, 716.5 - 
716.6,  
716.8 - 716.9, 725 
M05 - M09, M10.x, M12, 
M13, M31.6, M35.3, 
M35.9 
Use of Durable Medical 
Equipment (CPT/HCPCS 
CODES) 
E0000, E0100, E0105, E0130, E0135, E014X, E0153-E0159, 
E016X, E0170-E0171, E0240, E0245, E0247-E0248, E0291, 
E0293, E0295, E0297, E0303-E0304, E0621, E0625, E0630, 
E0637-E0638, E0641-E0642, E095X, E0961, E0966-E0967, 
E0790, E0972-E0979, E0981-E0986, E0988, E0990-E0993, 
E0995, E1002- E1012, E1014-E1018, E1028-E1031, E1035-
E1036, E1038-E1039, E1065-E1066, E1069, E1160-E1161, 
E1220-E1228, E1230-E1238, E1296-E1298, E220X, E2210-
E2215, E2218- E2222, E2224-E2228, E2231, E2291, E2293-
E2294, E2300-E2301, E2310-E2311, E232X, E2330-E2331, 
E2340-E2343, E2350-E2351, E2358-E2359, E236X, E2370-
E2378, E238X, E2390-E2397, E260X, E261X, E262X, 
E2630-E2633, K000X, K002X, K003X, K004X, K008X, 
K0050- K0058, K0062-K0063, K0069-K0073, K0077, 
K0079, K008X, K0098, K0103, K0105, K0107-K0108, 
K0195, K0460-K0461, K065X, K066X, K0800-K0802, 
K0806-K0808, K0812-K0816, K082X, K0830-K0831, 
K0835-K0843, K0848-K0849, K085X, K0860-K0864, 
K0868-K0871, K0877-K0880, K0884-K0886, K0898-K0900, 
T1000-T1005, T1019-T1022, T1030-T1031 
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Fall or Fall related 
diagnoses: Hip fractures  
Or subdural hematoma 
Or subarachnoid 
hematoma 
430, 733.14, 733.96, 800 - 801, 
803, 835, 852, E880, E884.2 - 
E884.9, E885.9, E887, E888, 
V15.88,432.1  
Z91.81, I60.9, I62.00, 
M84.459A, M84.359A, 
W19.XXXA, Z98.1, S06.6, 
S06.7 
Fatigue 780.71, 780.79 R53.x, G93.3 
Gait Abnormality  
or difficulty walking 
781.2 - 781.4, 719.7 R26.x, R27.0, R27.8, 
R27.9, R29.5 
Parkinson’s Disease and 
Tremors 






440 - 444, 447, 451 - 453, 557 170.x - I74.x, I77.x, I80.x - 
I82.x, I73.9, K55.0 
Muscular wasting and 
disuse atrophy, cachexia, 
or debility 
307.1, 728.2, 728.87, 783, 
799.3 - 799.4 
F50.00, M62.5, M62.81, 
R63.0, R64, R54, R53.81 
Hearing 
Impairment/Hearing Aid 
388.0 - 388.2, 389.9 , V53.2  H91.90, H91.23, Z46.1, 
Z97.4 
Peripheral Neuropathy 250.7, 337.00, 337.09, 337.1, 
356.4, 356.8, 357.1 - 357.7, 
356.9  
E11.51, H47.10, G90.09, 
G99.0, G60.3, G60.8, G63, 
E08.42, E09.42, E10.42, 






365.2 - 365.7, 365.81-365.82, 
365.89, 365.9, 368.30-368.31, 
368.4, 368.60, 368.62-368.69, 
368.7 - 368.9, 377.75, 369.x  
H35.3x, H40, H53.60 - 
H53.69, H53.8 - H53.9, 
H47.619, H42, H54 
Dementias (Alzheimer’s, 
Vascular, Lewy Body, 
Pick’s disease, Mild 
Cognitive Impairment, 
etc.) 
290.0 - 290.4, 291.1 - 291.2,  
293.0 - 293.1, 294.8 - 294.9, 
331.0,  
331.10 - 331.11, 331.82 - 
331.83, 331.92, 333.4, 438.0, 
780.09, 780.93, 799.5 
F00 - F09, F10.96, F10.27, 
G30.9, G31.01, G31.83 - 
G31.84, G10, I69.91, 
R40.0, R40.1, R41.2 - 
R41.3 
Anxiety 293.84, 300.0 - 300.1, 309.21, 
309.24, 309.28 
F06.4, F40.x, F41.x, F93.0 
- F93.2, F43.22 - F43.23 
Depression or Bipolar 296, 298.0, 309.0 - 309.1, 311 F31.4, F43.21, F32.9, 
F32.3, F33.3 
F30.x, F31.x 
Chronic Pain 338.29, 724.5, 338.4  G89.2x, M54.89, M54.9, 
G89.4 
Failure to thrive 783.7 R62.7 
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